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                                                                    ABSTRACT
AIM OF THE STUDY: To evaluate Tissue Doppler as a tool in detecting dyssynchrony in patients 
with LBBB.
METHODS: From an initial cohort of patients with LBBB, 38 patients with low ejection fraction ≤ 50 
and 31 with normal LV systolic function, all comparable in age and sex underwent standard Doppler 
echo, ECG and Tissue Doppler Imaging. The precontraction time [PCTm from the beginning of Q 
wave of ECG to the onset of Sm] was calculated as an index of myocardial systolic activation in five 
different  basal  myocardial  segments  (LV anterior,  inferior,  septal,  lateral  walls  –RV lateral  wall). 
Intraventricular systolic dyssynchrony was analyzed by difference of PCTm in different LV myocardial 
segments. Interventricular activation delay was calculated by the difference of PCTm between the most 
delayed LV segment and RV lateral wall. 
RESULTS: Patients with low LV ejection fraction showed increased qrs duration and LV end diastolic 
diameter. By DMI these patients showed increased intraventricular delay [p=0.03] in activation of the 
LV lateral wall.  They also showed increased interventricular dyssynchrony [p=0.006]. By receiving 
operating characteristic [ROC] curve analysis, a cut off value of 48.5msec of interventricular delay 
showed 71% sensitivity and 65% specificity in identifying patients with impaired ejection fraction. In 
the  overall  population by use of  stepwise forward multivariate  linear  regression analyses,  LV end 
diastolic diameter,  ejection fraction and qrs duration were the only determinants of interventricular 
activation delay. 
CONCLUSIONS: Pulsed DMI is an effective noninvasive technique for assessing the severity of 
regional delay in activation of ventricular walls in patients with LBBB. The impairment of 
interventricular systolic synchronicity is strongly related to LV dilatation and systolic dysfunction. By 
knowing the exact delay in contraction of the various myocardial segments patients with dilated 
cardiomyopathy suitable for cardiac resynchronization therapy may be better selected.  
INTRODUCTION
Left bundle branch block (LBBB) generally associated with structural heart disease is a frequent 
conduction disorder. In patients with LBBB and structural heart disease, overall mortality is 
significantly increased.1-4 Moreover, it is also known that the incidence of cardiovascular disorders and 
subsequent mortality is increased in isolated LBBB5. In the presence of LBBB, due to delay of left 
ventricular (LV) mechanical activity, interventricular dyssynchrony and abnormal interventricular 
septal movement occurs. As a result of abnormal septal movement, stroke volume, ejection fraction 
(EF), and LV filling are decreased.6-8Recently, cardiac resynchronization therapy (CRT) is advocated in 
heart failure in patients with NYHA class III, IV on maximum antifailure medication with wide QRS 
complex (≥ 130 msec) and decreased EF (≤ 35 %). 9-11 Results from mechanistic studies, observational 
evaluations and randomized control trials have constantly demonstrated significant improvement in 
quality of life, functional status and exercise capacity in patients with New York Heart Association 
(NYHA) class III and IV heart failure who are assigned to active resynchronization therapy. The 
studies in such patient population have revealed the presence of intraventricular dyssynchrony among 
various LV segments together with interventricular dyssynchrony.12-16 Furthermore different trials 
suggest that this treatment modality yields the best hemodynamic benefits in patients with documented 
intraventricular dyssynchrony irrespective of the QRS duration. 12-17  Conversely no recent data is 
available on regional systolic dyssynchrony in patients with LBBB and normal LV ejection fraction. In 
our study, we looked for the presence of intra and interventricular dyssynchrony using Tissue Doppler 
Imaging in patients with LBBB with both normal and compromised LV function.
AIMS OF THE STUDY
1. To find out what proportion of Indian patients with congestive cardiac failure and LBBB on 
ECG are candidates for cardiac resynchronization therapy based on echocardiographic 
characteristics.
2. To evaluate the determinants of myocardial activation delay of both left and right ventricle in 
patients with LBBB demonstrating either normal or impaired global LV systolic function.
OBJECTIVES OF THE STUDY
The study was undertaken with the following objectives.
1. To determine the prevalence of cardiac dyssynchrony by echocardiographic evaluation in 
patients with LV dysfunction and LBBB.
2. To determine the prevalence of cardiac dyssynchrony by echocardiographic evaluation in 
patients with normal LV systolic function and LBBB.
3. To evaluate whether QRS width is a reliable method to detect dyssynchrony
4. To test whether patients with LBBB and low ejection fraction have greater dyssynchrony than 
those with LBBB and normal LV systolic function.
REVIEW OF LITERATURE
Left Bundle Branch Block
          Left bundle Branch Block (LBBB) results from conduction delay or block in any of several sites 
in the intraventricular conduction system, including the main left bundle branch, in each of the two 
fascicles, or less commonly within the fibers of the bundle of His that become the main left bundle 
branch. The result is extensive reorganization of the activation pattern of the left ventricle.
ECG Abnormalities
LBBB produces a prolonged QRS duration, abnormal QRS complexes and ST-T wave abnormalities 
(Fig 1).
Commonly accepted diagnostic criteria are 14
1. QRS duration ≥ 120 msec
2. Broad, notched R waves in lateral precordial leads (V5 and V6) and usually leads I and aVL.
3. Small or absent initial r waves in right precordial leads (V1 and V2) followed by deep S waves
4. Absent septal q waves in left-sided leads
5. Prolonged intrinsicoid deflection (>60 msec) in V5 and V6
Fig 1
The mean QRS axis with LBBB is highly variable .It can be normal, deviated to the left, or, less often, 
deviated to the right. Left axis deviation is associated with more severe conduction system disease that 
includes the fascicles as well as the main left bundle, whereas right axis deviation suggests dilated 
cardiomyopathy with biventricular enlargement.
ST-T wave changes are also prominent with LBBB. In most cases, the ST wave and the T wave are 
discordant with the QRS complex; that is, the ST segment is depressed and the T wave is inverted in 
leads with positive QRS waves (leads I, aVL, V5 and V6), while the ST segment is elevated and the T 
wave is upright in leads with negative QRS complexes (Leads V1 and V2)
Mechanisms of ECG abnormalities
The ECG abnormalities of LBBB result from an almost completely reorganized pattern of left 
ventricular activation .Initial septal activation occurs on the right (rather than on the left) septal surface, 
resulting in the absence of normal septal q waves in the ECG.
The excitation wave then spreads slowly, by conduction from muscle cell to muscle cell, to the left side 
of the septum; the earliest ventricular activation begins as late as 30 to 50 msec into the QRS complex. 
Endocardial activation of the left ventricle may then require an additional 40 to more than 180 msec, 
depending largely on the functional status of the distal left bundle and Purkinje system. Thus, the 
overall QRS complex is prolonged and can be very wide in patients with, for example, diffuse 
ventricular scarring from prior myocardial infarction.
Once left ventricular activation begins, it proceeds in a relatively simple and direct manner around the 
free wall, and finally, to the base of the heart. This is in contrast to the multicentric, overlapping 
patterns of activation seen under normal conditions. Direct progression of activation across left 
ventricle projects continuous positive forces to left sided-leads and continuous negative forces to right 
sided-leads. Spread predominantly through working muscle fibers rather than the specialized 
conduction system results in notching and slurring as a consequence of discontinuous anisotropy.
The discordant ST-T wave pattern is a result of the transventricular recovery gradients referred to 
earlier. With LBBB, the right ventricle is activated and recovers earlier than the left, so recovery 
vectors or dipoles are directed toward the right and away from the left. Hence, positive ST-T waves 
will be registered over the right ventricle and negative ones over the left ventricle.
Clinical significance
LBBB usually appears in patients with underlying heart disease .It is associated with significantly 
reduced long term survival and with 10 year survival rates as low as 50 percent, probably reflecting the 
severity of the underlying cardiac disease. Among patients with coronary artery disease, the presence of 
LBBB correlates with more extensive disease, more severe left ventricular dysfunction and reduced 
survival rates. The duration of the QRS complex in LBBB correlates inversely with left ventricular 
ejection fraction. Patients with associated left or right axis deviation have more clinical manifestations.
In addition to the hemodynamic abnormalities produced by these underlying conditions, the abnormal 
ventricular activation pattern of LBBB itself induces hemodynamic perturbations, including abnormal 
systolic function with dysfunctional contraction patterns, reduced ejection fraction, lower stroke 
volumes and abnormal diastolic function; reversed splitting of the second heart sound and functional 
mitral regurgitation are common.
Ventricular Dyssynchrony: A pathophysiological cause or contributor to heart failure
Patients with left ventricular (LV) systolic dysfunction and dilation, with or without clinical signs or 
symptoms of heart failure, frequently have ventricular conduction delays. Approximately one third of 
patients with systolic heart failure have a QRS duration greater than 120 ms, which is most commonly 
seen as left bundle-branch block (LBBB). In LBBB, the left ventricle is activated belatedly through the 
septum from the right ventricle, resulting in a significant delay between the onset of left ventricular 
(LV) and right ventricular contraction.6 Activation of the anterior septum precedes inferoseptal 
activation, with the latest activation occurring in the inferior and lateral aspects of the left ventricle. 
(Fig 2)
The interventricular septum exhibits a normal (early) contraction resulting in paradoxical septal 
motion. LBBB is associated with significantly later aortic opening, aortic valve closure, and mitral 
valve opening but does not affect the timing of right ventricular events. The delay in aortic valve 
closure leads to a relative decrease in the duration of LV filling. In patients with LBBB, delayed 
depolarization or abnormal repolarization can result in regional myocardial contraction into early 
diastole, causing a delay of mitral valve opening and also shortening LV filling time.6
Patients with LBBB commonly have abnormal ventricular septal motion, which is related to the 
Fig 2
interventricular dyssynchrony and the resulting abnormal pressure gradient between the left and right 
ventricles.6 Because of the abnormal septal motional end-systolic diameter is increased and regional 
septal ejection fraction is decreased in patients with LBBB. LBBB patients with or without cardiac 
disease can reduce global LV ejection fraction (LVEF) and decrease cardiac output, mean arterial 
pressure, and dp/dt. 15 Moreover with ventricular dyssynchrony, mitral valve closure might not be 
complete because atrial contraction is not followed by a properly timed ventricular systole. If the time 
lag is long enough, a ventricular-atrial pressure gradient can develop and cause diastolic mitral 
regurgitation.16
The abnormal activation sequence induced by spontaneous LBBB or by right ventricular (RV) pacing 
generates changes in regional ventricular loading conditions, possibly redistributes myocardial blood 
flow17 and creates a regional non uniform myocardial metabolism.18 These effects of ventricular 
dyssynchrony might contribute to disease progression in LV systolic dysfunction patients . For 
example, studies in experimental heart failure induced by rapid ventricular pacing showed regional 
differences in the extent of ventricular hypertrophy with an apicobasal and septolateral-oriented 
gradient.19 Moreover, experimentally induced LBBB has demonstrated a large effect on the expression 
of regional stress kinases and calcium-handling proteins.20 Preliminary evidence suggests that the 
expression of p38-MAPK(a stress kinase) is significantly elevated in the endocardium of the late-
activated region, whereas phospholamban is significantly decreased.19 In addition, sacro(endo)plasmic 
reticulum Ca2+-ATPase is decreased in the region of early activation.
In patients with LV dysfunction, ventricular dyssynchrony places the already failing left ventricle at an 
additional mechanical disadvantage. Ventricular dyssynchrony appears to have a deleterious impact on 
the natural history of heart failure, as a wide QRS complex has been associated with increased 
mortality in patients experiencing heart failure.21 On the basis of these observations, investigators 
hypothesized that patients with LV dysfunction and delayed ventricular conduction would benefit from 
pacing at sites that achieve a more rapid ventricular depolarization and thus a more synchronous 
contraction, or result in a more favorable contraction pattern, and correct interatrial and/or 
interventricular conduction delays to maintain optimal atrial-ventricular (AV) synchrony. Shortening 
activation might also prolong the time available for myocardial perfusion. In the mid-1990s, such 
notions led to the evaluation of atrial synchronized biventricular pacing as a means to resynchronize 
ventricular contraction and thus improve the function of the heart as a pump.
The meaning of such complex interactions between changes in regional loading conditions, blood flow 
distribution, regional myocardial metabolism, and gene and protein expression induced by an abnormal 
activation sequence is not fully understand. However, it is likely that these consequences of ventricular 
dyssynchrony lead to rearrangement of both contractile and noncontractile cellular elements and 
perhaps the extra cellular matrix in the heart, thus stimulating the process of ventricular remodeling. 
Thus, it is inconceivable that dyssynchrony represents a newly appreciated pathophysiological process 
that directly depresses the ventricular function and ultimately leads to ventricular dilatation and heart 
failure. Evidence from recent clinical trials comparing RV pacing versus either no pacing or atrial 
pacing in patients with LV systolic dysfunction supports this notion. In the dual chamber and VVI 
implantable defibrillator (DAVID) trial, RV pacing was associated with heart failure disease 
progression, including an increased incidence of worsening heart failure. 22
Mechanisms of action of CRT
At the present time, we recognize 4 levels of electromechanical abnormalities that may be treated by 
CRT.
1) Atrioventricular delay
2) Interventricular delay
3) Intraventricular delay
4) The most recently described 23 intramural delay
Although the effect of CRT on the intramural delay has not been full investigated, the effect on 
interventricular delay probably plays a second role after the correction of both atrioventricular and 
intraventricular delay. The mechanisms by which cardiac resynchronization therapy improves 
mechanical LV function in patients with heart failure and ventricular dyssynchrony are not completely 
understood. Electrical resynchronization can reduce the LBBB-induced mechanical interventricular 
dyssynchrony between the right and the left ventricle and the intraventricular dyssynchrony within the 
left ventricle.
Preexcitation of the LV lateral wall with atrial synchronous left or biventricular pacing in heart failure 
patients with ventricular conduction delay can resynchronize the ventricular activation pattern by acting 
as an electrical bypass, thus restoring a more coordinated ventricular contraction. This novel approach 
to treat heart failure is called CRT. Minimizing intraventricular dyssynchrony has been shown to 
improve global LV function; i.e. cardiac resynchronization therapy increases LV filling time, decreases 
septal dyskinesis and reduces mitral regurgitation, thus improving hemodynamics (Fig 3). Shortening 
or optimizing the atrioventricular interval necessary to resynchronize lateral-septal wall contraction 
also improves atrioventricular mechanical synchrony by abolishing the late diastolic ventriculoatrial 
gradient and so called “presystolic” mitral regurgitation, which is seen in association with ventricular 
dyssynchrony, and prolongs ventricular filling time. Pacing for the left lateral wall especially from the 
proximity of 
the posterior papillary muscle produces early activation of the papillary muscle region and can decrease 
systolic mitral regurgitation.
Optimization of ventricular loading conditions as provided by CRT improves myocardial efficiency 
and increases systolic function and LV contractibility with a neutral or moderately positive effect on 
diastolic function. When combined, these various mechanical effects of CRT improve the function of 
the heart as a pump.
Cardiac resynchronization therapy can improve the deranged neurohormonal milieu associated with 
chronic heart failure. There is increasing evidence from unpublished investigations suggesting 
improvement of brain natriuretic peptide and a variety of other neurohormones in more recent studies. 
There is also an indication that cardiac resynchronization therapy restores autonomic balance in heart 
failure. In 2 prospective studies, biventricular pacing resulted in a significant improvement in heart rate 
variability, suggesting a decrease in cardiac adrenergic activity or an increase in parasympathetic 
activity, or a combination of both.24,25
Clinical Studies of cardiac Resynchronization Therapy
Although early biventricular pacing studies used epicardial leads to pace the left ventricle, later studies 
used market-available transvenous leads that could be inserted into a distal cardiac vein through the 
coronary sinus to pace the LV free wall. This approach eliminates the need for general anesthesia and 
Fig 3
thoracotomy to place an epicardial lead and, thus could be safer for fragile patients experiencing heart 
failure. As a result of the favorable outcomes of these early observational studies, randomized controlled 
trials to evaluate the long-term subjective and objective results of biventricular pacing have been 
performed. Several trials have been recently completed; others are currently underway (Table 1). These 
studies include the pacing therapies in congestive Heart Failure (PATH-CHF) trial, the Multisite 
Stimulation in Cardiomyopathy (MUSTIC) study, the MIRACLE trial, MIRACLE ICD, the VENTAK-
CHF/CONTAK CD trial, the Cardiac Resynchronization in Heart Failure (CARE HF) trial, and the 
comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.
Table 1.   Randomized, Controlled Trials of Cardiac Resynchronization Therapy in Heart Failure
Study Design Patients Results
PATH-CHF24
MUSTIC26
MIRACLE9
MIRACLE 
ICD27
CONTAK CD28
Single-blind, 
randomized,
crossover, 
controlled
European 
randomized, 
crossover
Study
Prospective, 
randomized,
double-blind, 
parallel- 
controlled
Prospective, 
multicenter,
randomized, 
double-blind,
parallel-
controlled
Prospective, 
42 patients with idiopathic or 
ischemic dilated 
cardiomyopathy and NYHA 
class III/IV heart failure
Group I: 47 patients with 
NYHA class III heart failure, 
Normal sinus rhythm; group 
II: 41 patients with persistent 
atrial fibrillation and slow 
ventricular response
453 patients with idiopathic or 
ischemic dilated 
cardiomyopathy, NYHA class 
III/IV heart failure, LV
dysfunction, and IVCD
560 patients with idiopathic or 
ischemic dilated
cardiomyopathy, NYHA class 
II-IV heart failure, LV
dysfunction, and IVCD with 
an indication for an ICD
581 patients with idiopathic or 
Interim analysis (spring 1998) 
showed a trend toward an 
improvement in all primary and 
Secondary end points with 
biventricular pacing.
Improved exercise capacity (6-
minute hall walk),NYHA class, 
and quality of life in normal sinus 
rhythm group; magnitude of 
improvement less in
atrial fibrillation group
Significant improvements in 
exercise capacity, NYHA class, 
quality of life, cardiac structure 
and function (by ECHO), 
composite clinical response,
and significant reductions in 
worsening heart failure, and a 
combined measure of morbidity 
and mortality
Significant improvements in 
exercise capacity, NYHA class, 
quality of life, and composite 
clinical response, in class III-IV 
patients; results in class
II patients have not yet been 
reported
Trend toward decreased morbidity/
COMPANION10
CARE HF29
randomized, 
crossover,
and parallel-
controlled
Multicenter, 
prospective,
randomized, 
controlled
Multicenter, 
prospective,
randomized, 
controlled
ischemic dilated 
Cardiomyopathy(248 in the 3-
month crossover study and 333 
in the 6-month parallel 
controlled phase),symptomatic 
heart failure (LVEF _35%), 
and IVCD with an indication 
for an ICD
1520 patients (planned 
enrollment of 2200) with 
dilated Cardiomyopathy, 
NYHA class III-IV heart 
failure, and an IVCD received 
1 of 3 therapies: drug therapy 
only; drug therapy and cardiac
resynchronization; or drug 
therapy and cardiac 
resynchronization/ICD
800 patients with idiopathic or 
ischemic dilated 
cardiomyopathy randomized to 
CRT device optimal
medical therapy vs optimal 
medical therapy only
mortality end point; improvements 
in exercise capacity, quality of life, 
and NYHA class
Significant reduction
in primary end point of all-cause 
mortality plus all-cause 
hospitalization
CRT was associated with a 36% 
reduction in the risk of mortality 
and a 46% reduction in the 
combined endpoint of death or 
heart failure hospitalizations
PATH-CHF
The PATH-CHF trial was a single-blind, randomized, crossover, controlled trial designed to evaluate 
the acute hemodynamic effects and to assess the long-term clinical benefit of right ventricular, LV and 
Biventricular pacing in patients with moderate-to-severe chronic heart failure and interventricular 
conduction block. 24 During the cross-over periods, patients were assigned to 2 different pacing modes 
(best univentricular versus biventricular pacing), each 4 weeks long with a 4-week control phase in 
between. This was followed by a chronic pacing phase. The effects of pacing on oxygen consumption 
at peak exercise and anaerobic threshold during cardiopulmonary exercise testing and on 6-minute hall 
walk distance were selected as primary end points of this study. Secondary end points were changes in 
NYHA class, quality of life (assessed by Minnesota Living with Heart Failure questionnaire), and 
hospitalization frequency. Changes in LVEF, cardiac output, and filling pattern were also assessed by 
echocardiography.
Forty-two patients were enrolled. Aortic pulse pressure and dp/dt were measured at baseline and during 
acute pacing. Acutely, biventricular and LV pacing increased dp/dt and pulse pressure more than right 
ventricular pacing (p<0.01). Chronic results were encouraging, with a tend toward improvement in all 
primary and secondary endpoints during pacing being noted.24 However, the results are weakened by 
the small number of patients studied, the single-blind design, and the observation that functional end 
points did not return to baseline during the “pacing-off” control or washout period. However with 
chronic pacing, statistically significant reductions in end-systolic and end-diastolic volumes were also 
demonstrated.
MUSTIC
The MUSTIC trial was also a single-blind, randomized, crossover evaluation of cardiac 
resynchronization therapy.26   Sixty seven patients were enrolled, 58 were randomized, and 47 
completed both study phases of the study. Inclusion criteria were normal sinus rhythm, no indication 
for pacing, NYHA class III congestive heart failure, optimized drug therapy, LVEF <35%, LV end-
diastolic dimension >60 mm, intraventricular conduction defect (IVCD) (QRS >150 ms), and 6-minute 
walk <450 m. Each phase of the study then lasted 3 months. Patients were randomized to active cardiac 
resynchronization or to no pacing and then crossed over to the alternative study assignment. The 
primary end point was the change in distance walked in 6 minutes, and secondary end points included 
change in quality of life, NYHA class, peak V˙O2, hospital admissions, worsening heart failure, total 
mortality, and patient preference for pacing mode.  Significant improvement was shown in all of these 
end points. For example, during the active pacing phase, the mean distance walked in 6 minutes was 
23% greater than during the inactive pacing phase (P<0.001). 
A “second” MUSTIC (MUSTIC-AF) trial evaluated similar end points in heart failure patients with 
atrial fibrillation and ventricular dyssynchrony resulting from a paced QRS duration of  >200 ms.30 
Although the number of patients completing the MUSTIC AFIB trial was smaller, significant 
improvements were seen in the primary and secondary end points.
MIRACLE
MIRACLE was the first prospective, randomized, double-blind, parallel-controlled clinical trial 
designed to validate the results from previous cardiac resynchronization studies and to further evaluate 
the therapeutic efficacy and mechanisms of potential benefit of cardiac resynchronization therapy.9 
Primary end points were NYHA class, quality-of-life score (using the Minnesota Living with Heart 
Failure questionnaire),
and 6-minute hall walk distance. Secondary end points included assessments of a composite clinical 
response, cardiopulmonary exercise performance, neurohormone and cytokine levels, QRS duration, 
cardiac structure and function, and a variety of measures of worsening heart failure and combined 
morbidity and mortality. 
The MIRACLE trial began in October 1998 and was completed late in 2000. Four hundred fifty-three 
patients with moderate to severe symptoms of heart failure associated with LVEF <35% and a QRS 
duration >130 ms were randomized (double-blind) to cardiac resynchronization (n=228) or to a control 
group (n=225) for 6 months, whereas conventional therapy for heart failure was maintained.9 Compared 
with the control group, patients randomized to cardiac resynchronization demonstrated a significant 
improvement in quality of life score (-18.0 versus -9.0 points, P=0.001), 6-minute walk
distance (+39 versus  +10 meters,  P=0.005), NYHA functional class ranking (-1.0 versus 0.0 class, 
P<0.001), treadmill exercise time (+81 versus +19 seconds, P=0.001), peak V˙O2 (+1.1 versus+0.1 mL/
kg per minute, P<0.01), and LVEF (+4.6% versus 
-0.2%, P<0.001). Patients randomized to cardiac resynchronization therapy demonstrated a highly 
significant improvement in a composite clinical heart failure response end point compared with control 
subjects, suggesting an overall improvement in heart failure clinical status.
By intention-to-treat, there were 16 deaths in the control group and 12 deaths in the resynchronization 
group (P=not significant). When compared with the control group, fewer patients in the cardiac 
resynchronization group required hospitalization (8% versus 15%) or intravenous medications (7% and 
15%) for the treatment of worsening heart failure (Figure 4). In the control group, there were 50 
hospitalizations for heart failure in 34 patients for a total of 363 heart failure hospital days during the 6-
month period of double-blind follow-up. In patients randomized to cardiac resynchronization, there 
were 25 hospitalizations for heart failure in 18 patients for a total of 83 heart failure hospital days 
(P=0.015 for the difference in risk of hospitalization, P=0.012 for the difference in hospital days), 
resulting in a 77% decrease in total days hospitalized over 6 months compared with the control group. 
Implantation of the device was unsuccessful in 8% of patients.
                      
Figure 4. Effect of cardiac resynchronization therapy on morbidity and mortality in MIRACLE. Although underpowered to evaluate mortality alone, the 
MIRACLE trial demonstrated statistically significant reduction in measures of heart failure morbidity (hospitalization for worsening heart failure and 
worsening heart failure requiring treatment with an intravenous medication) and combined morbidity and mortality favoring cardiac resynchronization 
therapy compared with controls. The figure represents mean patient estimates ± 95% confidence intervals.
VENTAK-CHF/CONTAK-CD
The VENTAK-CHF/CONTAK-CD study was also a randomized, controlled, double-blind study 
comparing active cardiac resynchronization therapy versus no pacing.31The initial design was that of a 
3-month crossover trial; this was later changed to a 6-month parallel control study design. The device 
used in the study combines ICD capabilities with biventricular pacing. Patients included had NYHA 
Fig 4
functional class II–IV heart failure, LVEF ≤35%, QRS duration >120 ms, and an accepted indication 
for an ICD. The primary end point was a composite of mortality, hospitalizations for heart failure, and 
episodes of ventricular tachycardia or ventricular fibrillation. 
A total of 581 patients were randomized, 248 into the 3-month crossover study and 333 into the 6-
month parallel Controlled trial. For the primary composite end point, the study demonstrated an 
insignificant trend favoring the resynchronization group. However, peak V˙O2, 6-minute hall walk 
distance, quality of life, and NYHA class were significantly improved in the active pacing group 
compared with inactive control subjects, particularly in the NYHA class III–IV subgroup of patients. 
For example, in class III–IV patients randomized to active resynchronization therapy, peak V˙O2 
improved by 1.8 mL/kg per minute compared with no improvement in the control group (P=0.003). 
There was also a reduction in LV end-systolic and end-diastolic dimensions seen in the VENTAK-
CHF/CONTAK-CD trial.
MIRACLE ICD
The MIRACLE ICD study was designed to be nearly identical to the MIRACLE trial. MIRACLE ICD 
was a prospective, multicenter, randomized, double-blind, parallel-controlled clinical trial intended to 
assess the safety and clinical efficacy of another combined ICD and cardiac resynchronization system 
in patients with dilated cardiomyopathy (LVEF≤ 35%, LV end-diastolic diameter>55 mm), NYHA 
class III or IV heart failure (a cohort of class II patients was also enrolled), IVCD (QRS >130 ms), and 
an indication for an ICD. Primary and secondary efficacy measures were essentially the same as those 
evaluated in the MIRACLE trial, but also included measures of cardioverter–defibrillator function 
(including the efficacy of antitachycardia therapy with biventricular pacing). 
Of 369 patients receiving devices and randomized, 182 were control subjects (cardioverter defibrillator 
activated, cardiac resynchronization off) and 187 were in the resynchronization group (cardioverter 
defibrillator activated, cardiac resynchronization on). At 6 months, patients assigned to cardiac 
resynchronization had a greater improvement in median quality of life score (-17.5 versus -11.0, 
P=0.02) and functional class (-1 versus 0, P=0.007) than control subjects, but were no different than 
control subjects in the change in distance walked in 6 minutes (+55 meters versus +53 meters, 
P=0.36).27 Peak oxygen consumption increased by 1.1 mL/kg per minute in the cardiac 
resynchronization group versus 0.1 mL/kg per minute in control subjects (P=0.04), whereas treadmill 
exercise duration increased by 56 seconds in the resynchronization group and decreased by 11 seconds 
in control subjects (P=0.0006). The magnitude of improvement was comparable to that seen in the 
MIRACLE trial, suggesting that patients experiencing heart failure with an ICD indication benefit as 
much from cardiac resynchronization therapy as those patients without an indication for an ICD. 
Interestingly, the efficacy of biventricular antitachycardia pacing was significantly greater than that 
seen in the univentricular (right ventricular) configuration. This observation suggests another potential 
benefit of a combined ICD plus resynchronization device in such patients. Finally, no proarrhythmia 
was observed, and arrhythmia
termination capabilities were not impaired by the addition of resynchronization therapy.
COMPANION and CARE-HF
Begun in early 2000, COMPANION was a multicenter, prospective, randomized, controlled clinical 
trial designed to compare drug therapy alone to drug therapy in combination with cardiac 
resynchronization with or without an ICD in patients with dilated cardiomyopathy, an IVCD, NYHA 
class III or IV heart failure, and no indication for a device.10 The trial design called for randomization 
of 2200 patients into 1 of
3 treatment groups: group 1 (440 patients) receiving optimal medical care only, group II (880 patients) 
receiving optimal medical care and the Guidant CONTAK TR (biventricular pacing alone), and group 
III (880 patients) receiving optimal medical care and the CONTAK CD (combined heart failure/ 
bradycardia /tachycardia ICD device). The primary end point of the COMPANION trial was a 
combination of all-cause mortality and all-cause hospitalization. Secondary end points included a 
variety of measures of cardiovascular morbidity as well as all-cause mortality alone. 
After randomization of 1520 patients, the COMPANION trial was terminated prematurely in 
November 2002 at the recommendation of an independent data and safety monitoring board. 
COMPANION was designed as an event-driven study (target >950 primary events). As reported by the 
lead investigators (A.M. Feldman and M.R. Bristow during a late-breaking session at the 52nd Annual 
Scientific Sessions of the American College of Cardiology in Chicago, April 2003), 1000 events had 
occurred by November 18, 2002, resulting from a higher-than-expected event rate. The number of 
patients randomized to each treatment group was 308 to medical therapy alone, 617 to medical therapy 
plus resynchronization therapy, and 595 to medical therapy plus cardiac
resynchronization and an ICD. The average age of patients was 66 years and 68% were men. The mean 
LVEF was 23% and 85% of the patients were in NYHA class III. At baseline, angiotensin-converting 
enzyme (ACE) inhibitors (or angiotensin receptor blockers) were taken by 90% of patients, ß-blockers 
by 68%, and spironolactone by 55%. Compared with control patients (group 1), the primary end point 
was significantly reduced in both resynchronization groups, by 18.6% in group 2 and by 19.3% in 
group 3 patients (P=0.015 and 0.005, respectively). All-cause mortality was also reduced by 
resynchronization therapy: group 1 versus group 2 by 24% (P=0.12); group 1 versus group 3 by 43% 
(P=0.002). 
Another randomized, controlled morbidity and mortality trial is CARE-HF. This study compares 
optimal medical therapy alone with optimal medical therapy plus cardiac resynchronization (without an 
ICD) in 800 patients with NYHA class III or IV systolic heart failure and ventricular dyssynchrony 
determined by either electrocardiographic (QRS duration ≥ 150 ms) or echocardiographic (QRS 
duration ≥ 120 and <150 ms plus echocardiographic evidence of dyssynchrony) criteria.29 CARE-HF 
was fully enrolled as of March 2003. The CARE-HF trial was one of the first trials that documented a 
mortality benefit from CRT. At 2 years, the use of CRT was associated with a 37% reduction in the 
trial's primary endpoint (the composite of all-cause mortality or unplanned hospitalization for a 
cardiovascular event) compared with control. In addition, CRT was associated with a 36% reduction in 
the risk of mortality and a 46% reduction in the combined endpoint of death or heart failure 
hospitalizations. The results of the study remained consistent across various subgroups, including 
patients with and without ischemic heart disease.
CRT Induces Reverse Ventricular Remodeling
The benefits of reverse ventricular remodeling have been demonstrated by pharmacological agents, 
such as ß-blockers and angiotensin-converting enzyme (ACE) inhibitors, which improve ventricular 
geometry and function and reduce morbidity and mortality in heart failure patients.32,33  Acting through 
several mechanisms, including
redistribution of regional ventricular loading, reduction or abolition of mitral regurgitation, reduction of 
sympathetic activity, increase of parasympathetic activity, and others, CRT also induces reverse 
remodeling of the failing left ventricle. Hence, the left ventricle gets smaller and contractility is 
improved after a period of CRT. Moreover,
as mentioned above, functional mitral regurgitation is  reduced acutely  and chronically during CRT. 
The effects of CRT on reverse ventricular remodeling have been consistently demonstrated in all 
randomized prospective controlled studies and in smaller mechanistic studies. Although Yu et al have 
demonstrated both an onset as well as an offset of the favorable remodeling effects of CRT, it is not 
known whether reverse remodeling will sustain over the long term. Of note, CRT has mostly been 
implemented in addition to optimal medical therapy for heart failure (ACE inhibitors, ß-blockers, 
diuretics, and in many cases spironolactone); however, recent data from the Multicenter InSync 
Randomized Clinical Evaluation (MIRACLE) study have shown that reverse remodeling during CRT 
can also take place in patients not receiving ß-blocking agents. Another important issue—whether 
patients with different degrees of electrical or mechanical abnormality will show similar degrees of 
reverse remodeling - is still unclear.
Clinical Implications of Cardiac Resynchronization Therapy Data
Although clinical application of cardiac resynchronization therapy is still in its early years, some 
clinical guidelines can be suggested on the basis of data to date. Cardiac resynchronization therapy 
should be considered only in patients who remain symptomatic despite a stable and optimized medical 
regimen for heart failure. Unless patients are intolerant, that medical regimen should include an ACE 
inhibitor or ACE inhibitor substitute and a ß-blocker with a diuretic and digitalis as needed. 
Resynchronization therapy should not be seen as an alternative to medical therapy. Other criteria for
cardiac resynchronization include QRS duration ≥ 120 ms, LVEF ≤ 35%, and LV dilation.
At this point, cardiac resynchronization is appropriate for patients with NYHA functional class III or 
IV functional limitation. Not enough data are available in patients with
NYHA class II heart failure to routinely recommend it, although the application of resynchronization 
therapy at an earlier stage could theoretically prevent late heart failure related complications or slow 
disease progression. In addition, initial Food and Drug Administration labeling does not specify 
approval for cardiac resynchronization for patients in atrial fibrillation. Early data support its efficacy 
in the atrial fibrillation population; however, definitive data are lacking. Many such questions remain 
unanswered. Paramount among these is whether prospective predictors of response
exist to further guide patient selection. To date, the benefits of cardiac resynchronization therapy have 
been seen regardless of baseline QRS duration (>120 ms), bundle-branch
block pattern, and etiology of the heart failure. Very recent data suggest that resynchronization therapy 
could yield improvement in the patient with intraventricular dyssynchrony despite a normal QRS 
duration.34
If ventricular dyssynchrony is proven to be the best predictor of response to cardiac resynchronization 
therapy, the electrocardiographic morphology of the conduction delay
could become less significant in patient selection. Specifically, the question of whether patients with 
right bundle branch block (RBBB) morphology will respond must be
addressed. In small subsets of patients in both the MIRACLE and CONTAK-CD trials, patients with 
RBBB appeared to do as well as patients with LBBB. Other investigators have also shown a response 
to therapy in patients with a RBBB, but only when associated with intraventricular dyssynchrony. 
Future studies could help refine the indication in NYHA class III–IV patients, whereas other studies 
could expand the indication to those with milder forms of heart failure or lesser degrees of ventricular 
dyssynchrony. Information is emerging regarding the outcomes of biventricular versus LV pacing only. 
At this point, the results are indefinite and further investigations are warranted. Another obvious 
question is whether routine LV or biventricular pacing rather than traditional right ventricular apical 
pacing should be used once coronary sinus lead technology, implantation techniques, speed, and 
complication rates are similar to those of right ventricular endocardial leads.
As resynchronization therapy becomes more commonly used, clinicians should be aware that pacing 
nomenclature originally established in 1974 was updated recently to include
a “generic code” for multisite pacing therapy. The fifth position of the code is now used to indicate 
whether multisite pacing is present in (0) none of the cardiac chambers, (A) 1
or both atria, (V) 1 and both ventricles, or (D) any combination of atria and ventricles. To describe a 
patient with a DDDR (dual-chamber rate-adaptive) pacemaker with biventricular stimulation, the code 
would be DDDRV.
Limitations and Pitfalls of Cardiac Resynchronization Therapy
The success rate for placement of a transvenous cardiac resynchronization system has ranged from 
approximately 88% to 92% in clinical trials.35  This means that 8% to 12% of patients undergoing an 
implant procedure will not attain a functioning system using this approach. Patients with failed 
implants must then settle for either another attempt at
transvenous placement of the LV lead or epicardial placement of the lead, or they must resign 
themselves to no cardiac resynchronization therapy. Implant-related complications are similar to those 
seen with standard pacemaker and ICD technologies, with the additional risk of dissection or 
perforation of the coronary sinus. Although rare, this event could lead to substantial morbidity and even 
mortality in patients experiencing heart failure.
 In addition to satisfying the clinical criteria already discussed, the patient should be given some basic 
information before referral. Although it is healthy for the patients to be optimistic about the potential 
improvement from cardiac resynchronization therapy, caregivers must provide realistic information. 
Although most patients respond favorably to Abraham and Hayes Cardiac Resynchronization 2601 
biventricular pacing, patients should understand that just like the experience with any medication or 
any other therapeutic modality for heart failure and despite clinical trials data demonstrating significant 
improvement, not every patient has a subjective and/or objective response to resynchronization therapy. 
Finally, if the patient obtained subjective and objective clinical improvement after implantation of a 
resynchronization device, worsening of the patient’s heart failure symptoms suggests worsening of the 
primary pathologic process or loss of resynchronization, or both. Loss of resynchronization can be 
manifested as frank worsening of heart failure, or it could be more occult and appear as vague 
weakness or fatigue. A specific programming sequence should be performed in the clinic to determine 
capture thresholds and document that LV capture is present. It is possible that LV pacing thresholds are 
fine but resynchronization is lost for other reasons. 
Anything that frequently or consistently inhibits LV stimulation can lead to “desynchronization.” If the 
AV interval is too long and the patient’s intrinsic PR conduction inhibits biventricular pacing, 
deterioration can occur. The AV interval could have been programmed appropriately, but accelerated 
intrinsic AV conduction could result in loss of effective biventricular pacing. Frequent premature 
ventricular contractions can also inhibit ventricular pacing output. In this case, the etiology of the 
increasing ventricular ectopy should be determined. Management can require an alteration in the 
medical regimen for heart failure, specific antiarrhythmic therapy, or an ICD, depending on the amount 
of ectopy and whether ventricular tachycardia is nonsustained or sustained.
Despite these potential concerns, follow-up of the device itself and battery life are similar to that seen 
for contemporary dual-chamber pacemakers and ICDs. Optimal hemodynamic response from 
resynchronization will depend not only on the site of LV stimulation, but also on optimization of the 
atrioventricular interval and the timing between the right and left ventricle. Best techniques to achieve 
such optimization are still being defined.16 Another clinical problem that could result in new symptoms 
of heart failure is chronotropic incompetence, or inappropriate rate acceleration for a given 
physiological activity. In the patient with heart failure, this is probably less likely as a result of 
progression of intrinsic sinus node dysfunction than a change in medical regimen. If the heart failure 
management team has altered ß blocker therapy or any other medication, the result could be limitation 
of the patient’s chronotropic response
Recent data have demonstrated that mechanical dyssynchrony is not necessarily related to electrical 
dyssynchrony 36 and that the presence of substantial left ventricular (LV) dyssynchrony is a major 
predictor of response to CRT. Indeed, some patients with a wide QRS complex do not exhibit LV 
dyssynchrony, whereas some patients with a narrow QRS complex may demonstrate LV dyssynchrony 
37. These considerations suggest that the surface electrocardiogram may not be the optimal marker to 
select candidates for CRT. New imaging techniques, in particular various echocardiographic 
approaches, may be superior to select potential responders to CRT.
Echocardiographic Approach to alleviate mechanical dyssynchrony
Atrioventricular (AV) dyssynchrony
Atrioventricular dyssynchrony may be related to the dysfunction of both the sinus node and the AV 
node. While sinus node dysfunction induces chronotropic incompetence, abnormal conduction of the 
AV node results in: 
 a delay between atrial and ventricular contraction ("AV dyssynchrony"); 
 mitral valve incompetence with occurrence of late diastolic regurgitation; 
 shortened ventricular filling time, limiting net diastolic stroke volume; 
 atrial systole often occurs simultaneously with early passive filling, hence reducing LV filling 
38.
Interventricular dyssynchrony
Dyssynchronous electrical activation of the ventricles, as during left bundle branch block, is associated 
with the right ventricular events preceding those of the LV, locally different contraction patterns, 
abnormal distribution of mechanical work in the LV, deficiencies in regional perfusion, and, therefore, 
decreased mechanical performance. The delay in onset of LV contraction and relaxation produces 
interventricular dyssynchrony and affects mainly the interventricular septal motion and its contribution 
to LV ejection. Earlier onset of right ventricular contraction results in right ventricular ejection 
occurring during LV end-diastolic period. The higher pressure within the right ventricle reverses the 
transseptal pressure gradient and, therefore, displaces the septum into the LV 6.  
Intraventricular dyssynchrony
Coordinate LV contraction depends on normal ventricular activation. When a portion of the LV is 
prematurely activated, it generates regions of both early and delayed contraction that will contribute to 
altered LV performance 39. Early shortening or late shortening results in wasted work. The early 
contraction occurs when pressure is low and does not lead to ejection. The late contraction occurs at 
higher stress and results in paradoxical stretch of early contracting segments. The net result is a decline 
in systolic performance, an increase in end-systolic volume and wall stress, a delayed relaxation, and a 
decline in efficiency. 
It is currently unclear to what extent each of these different forms of dyssynchrony contributes to the 
severity of heart failure. Crucial, however, is that all different dyssynchronies are assessed to identify 
patients with a high likelihood of response to CRT.
Echocardiographic assessment and quantification of dyssynchrony
Conventional echocardiography
The AV dyssynchrony can be assessed from conventional echocardiography by evaluating the mitral 
inflow duration; to date, there are no specific criteria for AV dyssynchrony in the literature. 
Interventricular dyssynchrony can be evaluated by assessing the extent of interventricular mechanical 
delay (IVMD), defined as the time difference between left and right ventricular pre-ejection intervals 
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(Fig 5). An IVMD ≥40 ms is considered indicative of interventricular dyssynchrony 40. 
Measurement of the interventricular mechanical delay (IVMD) by Doppler echocardiography: the right ventricular and left ventricular (LV) 
preejection intervals are measured from the onset of the QRS on the electrocardiogram (ECG) to the onset of pulmonary (Pulm) (RV-PEI) and 
aortic (Ao) (LV-PEI) outflow; IVMD is calculated by subtracting the RV-PEI from the LV-PEI. 
M-mode echocardiography may be useful for assessing intraventricular dyssynchrony 12. Using an M-
mode recording from the parasternal short-axis view (at the papillary muscle level), the septal-to-
posterior wall motion delay (SPWMD) can be obtained ( Fig 6), and a cut-off value ≥130 ms was 
proposed as a marker of intraventricular dyssynchrony. However, frequently the SPWMD cannot be 
obtained, either because the septum is akinetic after extensive anterior infarction or because the 
maximal posterior motion is ill-defined. In addition, it is often not possible to obtain perpendicular M-
mode sections of the proximal LV.
Fig 6
Parasternal M-mode recording in a heart failure patient with left bundle branch block. The left ventricular cavity is dilated and shows severely 
reduced systolic function. A clear delay between peak systolic septal and posterior wall inward motion is observed 
Newer echocardiographic methods
Two newer methods have been described, both addressing intraventricular dyssynchrony. Breithardt et 
al41  evaluated 34 patients undergoing CRT using a semiautomatic method for endocardial border 
delineation. The degree of LV dyssynchrony was quantified in two-dimensional echocardiographic 
sequences from the apical four-chamber view, focusing on the septal-lateral relationships. Computer-
generated regional wall movement curves were compared by a mathematical phase analysis, based on 
Fourier transformation (Fig. 7). The resulting septal-lateral phase angle difference is a quantitative 
measure for intraventricular (dys)synchrony. 
 (A) End-diastolic still frame image in the apical four-chamber view with a semiautomatically drawn left ventricular endocardial contour tracing. 
(B) Left ventricular wall motion displacement (between end-diastole and end-systole) for 100 endocardial segments determined with the centerline 
method. (C) Averaged septal (dashed line) and lateral (solid line) wall motion from 40 adjacent septal and lateral segments and three to seven 
cardiac cycles displayed as displacement (mm) over time (s). The "shift" between the curves indicates the degree of regional dyssynchrony and can 
be expressed quantitatively by the regional phase angle difference 
Kawaguchi et al. 42 studied 10 patients with and without CRT, and, to optimize endocardial LV border 
detection, echocardiography contrast (Optison, Mallinckrodt, Hazelwood, Missouri) was used; the 
contrast-enhanced images were processed using a technique referred to as cardiac variability imaging. 
On the four-chamber images, the endocardial border was outlined manually and regional fractional area 
changes were determined and plotted versus time, yielding displacement maps. From these maps, the 
dyssynchrony between the septum and lateral wall was determined. 
Both methods are restricted by the use of a single imaging plane. Any dyssynchrony in other walls will 
be overlooked, and, thus, the precise extent of dyssynchrony cannot be measured. Three-dimensional 
echocardiography, with the better spatial resolution, may potentially overcome this limitation. An 
example of this approach is shown in Figure 8. However, the clinical feasibility of real-time three-
Fig 7
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dimensional echocardiography still has to be proven. 
Quantification of regional wall motion from real-time three-dimensional echocardiographic data. After semiautomatic segmentation of the left 
ventricular chamber (upper left), the extent and timing of regional wall motion is analyzed in a 16-segment model (lower left) and in this example 
expressed as regional ejection fraction over time. There is clear regional dyssynchrony between the inferoseptal and the anterolateral segments 
during left bundle branch block (LBBB) (lower middle), which improves immediately after initiation of cardiac resynchronization therapy (CRT) 
(lower right). 
Tissue Doppler Imaging (TDI), strain and strain rate, tissue tracking (TT)
Tissue Doppler Imaging allows measurement of peak systolic velocity of different regions of the 
myocardium, and timing of peak systolic velocity in relation to electrical activity (QRS complex). 
Based on these variables, TDI can provide accurate information on electromechanical coupling, and 
also assess interventricular and intraventricular dyssynchrony ( Fig 9). In addition, information on 
diastolic function can be obtained. Different groups have subsequently used TDI to assess 
dyssynchrony before CRT. Interventricular dyssynchrony was evaluated by Rouleau et al. who studied 
35 patients with dilated cardiomyopathy. Using TDI, the authors demonstrated an excellent agreement 
between QRS duration and interventricular dyssynchrony. Yu et al. used TDI to assess 
intraventricular(34)  dyssynchrony in 88 normal individuals, 67 patients with heart failure and a narrow 
QRS complex (≤120 ms), and 45 with a wide QRS complex (>120 ms). In this study, 12 sample 
volumes were placed in the myocardium, and for each sample the time from onset of QRS complex to 
peak systolic velocity was measured. From these data, two parameters indicating intraventricular 
dyssynchrony were derived: 
1. The maximal difference between peak systolic velocities of any 2 of the 12 segments 
(intraventricular dyssynchrony defined as a difference >100 ms); and 
2. The SD of all 12 time intervals measuring time to peak systolic velocity (intraventricular 
dyssynchrony defined as a standard deviation of 33 ms, also referred to as dyssynchrony index).
The authors demonstrated absence of substantial intraventricular dyssynchrony in normal individuals, 
whereas 73% of the patients with a wide QRS complex had substantial intraventricular dyssynchrony. 
Of interest, 51% of the patients with a narrow QRS complex also exhibited substantial intraventricular 
dyssynchrony. 
In other studies, intraventricular dyssynchrony was measured by placing two sample volumes (on the 
basal parts of the septum and lateral wall), and a delay ≥ 60 ms between peak systolic velocities of the 
septum versus lateral wall (referred to as "septal-to-lateral delay") was used as an indicator of the 
substantial intraventricular dyssynchrony.(43) Using the digitally stored color-coded tissue Doppler 
images, further extended off-line analysis can be performed (i.e., strain and strain-rate analysis). Strain 
analysis allows direct assessment of the degree of myocardial deformation during systole and is 
expressed as the percentage of segmental shortening or lengthening in relation to its original length 44 ; 
it provides important information on the timing of onset and peak of myocardial contraction, permitting 
measurement of (dys)synchrony. Compared with TDI, the main advantage of strain rate imaging 
resides in the better differentiation between active systolic contraction and passive displacement, which 
is of particular importance in ischemic patients with scar tissue.
(A) The typical Tissue Doppler Imaging tracings (peak systolic velocity [PSV], diastolic velocities [E' and A']) obtained in the septum of a normal 
individual. (B) Illustration of assessment of timing from onset of QRS to peak systolic velocity. (C) Evaluation of intraventricular (dys)synchrony 
by placing sample volumes on the septum (yellow curve) and lateral wall (green curve). Data from a normal individual showing complete 
intraventricular synchrony. (D) Severe intraventricular dyssynchrony between the septum (yellow curve) and lateral wall (green curve). 
The degree of systolic segmental shortening can be obtained with color-coded TDI by calculating the 
instantaneous regional velocity gradient (i.e., the strain rate, s−1) and integrating this information over 
time (strain, %). Recent studies have focused on the application of strain and TT for the detection of 
mechanical intraventricular dyssynchrony in patients considered for CRT, and particular attention was 
paid to events that occurred late in systole extending into the isovolumetric relaxation phase and 
diastole. In a typical patient with left bundle branch block and delayed lateral wall activation, a delay in 
the onset of lateral wall shortening (as compared with the septum) can be observed. However, the 
clinical applicability of strain rate imaging is still limited by artefacts and a poor signal-to-clutter ratio, 
which renders the image acquisition and analysis process time-consuming and tedious. Moreover, the 
technique is operator-dependent, which limits reproducibility and widespread use. 
Fig 9
Determinants of dyssynchrony in patients with LBBB
Chronic heart failure (CHF) is an active disease process characterized by progressive remodeling of the 
ventricles, even in patients with stable symptoms, and by progression within the conduction system. In 
fact, in approximately 30% of patients, CHF not only determines impaired cardiac systolic function, 
but also affects the conduction pathways causing a delay in the onset of both right (RV) and left (LV) 
ventricular systole. Such dyssynchrony is visible on the electrocardiogram as a QRS interval lasting 
more than 120msec.6
Several authors have reported that this intraventricular delay may further impair the ability of the 
failing heart to eject blood and enhance the severity of mitral valve regurgitation.6,40 In addition, such 
prolongation of QRS duration in patients with left bundle branch block (LBBB) on the ECG has been 
described as an index of increased risk of mortality.3 Devices using atrial-synchronized biventricular 
pacing to coordinate LV and RV contraction have been developed. Several recent studies have 
suggested that cardiac resynchronization can improve cardiac function, enhance the quality of life and 
reduce all-cause mortality.26
Pulsed Doppler myocardial imaging (DMI) extends Doppler applications beyond the analysis of 
cardiac blood flows to the measurement of myocardial wall motion. Several recent reports have 
documented the usefulness of DMI in assessing the severity of LV dyssynchrony in patients with 
LBBB and CHF, as well as in evaluating the pacing effects on long-axis function in these patients. 
Conversely, no recent data is available on regional systolic dyssynchrony in patients with LBBB and 
normal LV ejection fraction. On these grounds, the aim of the present study is to evaluate the 
determinants of myocardial activation delay of both left and right ventricle in patients with LBBB 
demonstrating either normal or impaired global LV systolic function.
                             MATERIALS AND METHODS
Study Design
This was a prospective descriptive trial performed over a 1 year period from October 2005 to October 
2006.
Setting
CMC Vellore is a 2000 bedded tertiary care teaching hospital. Patients were recruited from the 
outpatient department.
69 consecutive patients with LBBB on ECG were enrolled for the study.
Subjects
Inclusion Criteria
1. LBBB on baseline ECG
Exclusion Criteria
1. Patients on CRT/Pacemaker
2. Atrial fibrillation with fast ventricular rate
3. Unwillingness of the patient to be enrolled
4. Poor acoustic window
Clinical Assessment.
All patients were interviewed individually. Their history, duration and severity of the symptoms were 
ascertained. They were therafter subjected to a thorough clinical examination and signs of failure 
checked for. The drugs they were on and duration of therapy was noted. An ECG was done at the time 
of recruitment and this was used to determine the electrocardiographic variables.
Patients were diagnosed to have ischemic cardiomyopathy if they had history of a prior MI, diagnosed 
by standard criteria or angiographic evidence of significant coronary artery disease. The patients who 
did not satisfy the criteria for ischemic cardiomyopathy but had global hypokinesia with EF<40% were 
diagnosed to have non ischemic dialted cardiomyopathy.
Echocardiographic Protocol
After a standard echocardiographic study, these patients eligible for inclusion were informed about the 
study and informed consent was obtained. Standard Doppler echocardiography and Tissue Doppler 
Imaging were performed with the subjects in partial decubitus, by Acuson Sequoia ultrasound system 
equipped with Doppler myocardial imaging capabilities. A frequency transducer of 4 MHz was used 
for two dimensional, M-mode and Doppler imaging. All the measurements were obtained by taking the 
average of  ≥ 3 cardiac cycles.
2D Echo
LV Ejection fraction was measured using a commercially available software program that applied 
modified Simpson’s rule on this chamber and four chamber views.
M-Mode
The septum to posterior wall return delay was ascertained using the M-Mode short axis view taken at 
the level of the papillary muscles. It was obtained by measuring the shortest interval between the 
maximal posterior displacement of the septum and the posterior wall. A SPWMD longer than 130 
milliseconds was considered as an interventricular dyssynchrony marker.
Standard Doppler
Using Pulsed Doppler time from the Q wave to the start of RV ejection as assessed at the level of the 
RV outflow tract from a short axis parasternal view was measured. The time from the q wave to the 
start of LV ejection as assessed by pulsed Doppler at the level of the LV outflow tract from a 4-
chamber view was found out.
Interventricular Dyssynchrony Assessment
The difference between the time for LV activation (Q- A0) and time for RV activation (Q-pulm) 
determined the doppler interventricular delay. A valve > 40 msec was considered an indication of 
dyssynchrony.
Pulsed Doppler Myocardial Imaging
Pulsed DMI was performed by spectral pulsed Doppler signal filters , bypassing high pass filter ; 
adjusting Nyquist limit to 15-20 cm/sec (close to myocardial velocities), and using the minimal optimal 
gain. In apical 4- Chamber and 2 chamber views, a 5mm pulsed Doppler sample volume was 
subsequently placed at the level of 5 different basal myocardial segments. LV posterior septum , LV 
inferior wall , LV anterior wall, LV lateral wall (at the level of mitral annulus ) and RV lateral wall (at 
the level of tricuspid annulus). The apical view was chosen to obtain a qualitative assessment of the 
longitudinal regional wall motion at most simultaneous to Doppler inflow and outflow and to minimize 
the incidence angle between Doppler beam and longitudinal wall motion. By use of DMI the index of 
myocardial systolic activation in five different basal myocardial segments was calculated: 
Precontraction time (PCTm) (from the beginning of Q wave of ECG to the onset of Sm); 
intraventricular systolic synchrony was analysed by the difference of PCTm between the most delayed 
LV segment and RV lateral wall.(Fig10)
DMI PCTm of LV mitral annulus and of RV tricuspid annulus in a patient with dilated cardiomyopathy and LBBB. Interventricular delay (difference 
between the two parameters) was 80 msec. PCTm = myocardial precontraction time; LV = left ventricle; RV = right ventricle.
Statistical Methods
Determination of sample size
In order to determine the sample size a similar study done by Pio Caso et al 45 was chosen. One of the 
major outcomes of the study was a parameter called the intraventricular delay. The mean value of the 
intraventricular delay in those with normal ejection fraction was 20.8 ± 17.3 and in those with low 
ejection fraction was 35.6 ± 18.2. Based on this information we calculated the sample size of our study 
for two sample comparison of means by STATA software. Considering a 5% α error with a 2-sided test 
and 80% power we obtained a sample size of  23 in each arm.
Analyses
All the analyses were performed by SPSS for windows release 14.0 (Chicago, Illinois, USA). Variables 
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were presented as mean ± SD. T test for unpaired data and analysis of variance (ANOVA) test with 
Scheffe correction estimated differences among the groups. Linear regression analyses and partial 
correlation test by Pearson’s method were done to assess univariate relations. Receiver operating 
characteristic (ROC) curve analysis was performed to select optimal cut off values of DMI 
measurements. A 2 x 2 table was made for each of the parameters like LV dyssynchrony, RV-LV 
dyssynchrony , APED and a Pearson Chi square test was performed. Differences were significant at 
p<0.05 
RESULTS
During the period October 2005 to October 2006, 69 patients with LBBB on ECG were included in the 
study. Of these 38 patients – Group I had an ejection fraction less than 50% and 31 patients – Group II 
had a normal ejection fraction ≥ 50% (Table II). The two groups were comparable in age (57.5  ± 
12.48 in the low EF vs  59.03 ± 11.58 in the normal EF), sex male prevalence (24/38 in low EF vs 
20/31 in normal EF).There were 25 female (36.2%) and 44 male (63.8%) subjects. 56 subjects (81.2%) 
were euthyroid , 10 (14.5%) were hypothyroid and 3 (4.3%) were hyperthyroid. 44 subjects (63.8%) 
were diabetic , 41 (59.4%) were hypertensive and 49 (71%) were dyslipidemic. 25 (36.2%) individuals 
suffered from ischemic heart disease. 19 (27.5%) were smokers and 5 (7.2%) were alcohol consumers.
The qrs width was significantly greater in those patients with LBBB who had a low EF. However it 
was not found to correlate well with the ECHO parameters evaluating dyssynchrony Of the 69 patients, 
10 individuals satisfied the ECHO criteria that deemed that they would benefit by resynchronization 
therapy (SPWMD > 130 msec, IVMD> 40 msec, APED > 140 msec, intraventricular activation delay > 
65 msec and interventricular activation delay > 55 msec). 9 of these individuals had a ejection fraction 
less than 50% [Table III]. When compared to the Echo criteria, the ECG criteria (qrs ≥ 140 msec) to 
select patients who would benefit from CRT was only 88.9% sensitive and 41.4% specific. There was 
only an 18% agreement between the ECG and Echo criteria in selecting patients for CRT that occurred 
beyond chance [Table IV]. This proved beyond doubt that ECG criteria was grossly inadequate in 
selecting patients with dyssynchrony who would benefit from CRT.
The two groups were comparable in heart rate – 84.82 ± 15.12 in those with low EF versus 82.58 ± 
18.768 in those with normal EF. The qrs duration was significantly greater in those with low EF (Mean 
= 148.53 ± 18.557) versus those with normal EF (Mean = 135.71 ± 11.725 p value 0.001). The mean 
LVIDd in those with low EF was 62.68 ± 9.355 which was significantly greater than those with normal 
EF (48.35 ± 5.919 p<0.001). The individuals with low EF had significantly higher LVIDs (51.5 ± 8.7 
versus 35.5 ± 9.3 p<0.001), EDV (188.97 ± 59.89 versus 108.39 ± 30.177 p<0.001) and ESV (126.05 ± 
51.6 versus 47.35 ± 13.5) [Table II].
TDI analyses showed a prolonged precontraction time at the level of the LV lateral wall in those with 
low EF [Table VI]. The PCTm of the LV anterior wall was almost significantly higher in the group 
with low EF. The PCTm for the RV lateral wall, LV inferior wall and LV septum were not significantly 
different between the two groups [Table V]. Individuals of both groups showed a significant delay in 
activation of the LV lateral wall with consequent prolonged intraventricular delay [Fig 10]. The group 
with normal EF were found to have significantly less interventricular myocardial activation delay (p= 
0.006 Table XII); intraventricular mechanical delay (p=0.007 Table XIII); aortic pre ejection delay 
(p=0.002 Table XIV); intraventricular myocardial activation delay (p=0.03 Table XI). The septum to 
posterior wall motion delay was not significantly different between the 2 groups (p=0.07) [Table 
XV].The sensitivity and specificity of DMI measured time intervals was determined [Table XVI]. By 
ROC curve analysis, a cut off value of 48.5 msec of interventricular delay showed 71% sensitivity and 
65% specificity in identifying patients with impaired EF [Fig 11] .
In the overall population by use of stepwise forward multivariate linear regression analyses, LV end 
diastolic diameter (ß coefficient = 1.408; p<0.01) , Ejection fraction (ß coefficient = -1.05; p<.015) and 
qrs duration (ß coefficient = .753; p<.02) were the only independent determinants of interventricular 
activation delay [Table XVII].
Table II
Parameter Group I
Low EF ≤ 50
Group II
Normal EF > 50
P value
Ejection Fraction
Age
Pulse Rate 
QRS Duration
LVIDd
LVIDs
EDV
ESV
Q to Basal Lateral
Q to Basal Anterior
Q to Basal Inferior
Q to Basal Septal
Q to RV Lateral
Interventricular Delay
Intraventricular Delay
34.71 ± 6.2
57.5 ± 12.48
84.82 ± 15.12
148.53 ± 18.56
62.68 ± 9.36
51.5 ± 8.77
188.97 ± 59.89
126.05 ± 51.6
127.03 ± 49.41
97.71 ± 37.64
83.03 ± 41.21
79.13 ± 33.93
57.81 ± 21.76
74.68 ± 43.90
68.82 ± 40.68
55.9 ± 2.7
59.03 ± 11.58
82.58 ± 18.77
135.71 ± 11.73
48.35 ± 5.92
35.5 ± 9.33
108.39 ± 30.18
47.35 ± 13.5
103.16 ± 46.01
79.61 ± 37.83
73.23 ± 35.72
65.55 ± 35.09
58.61 ± 32.33
47 ± 35.52
47.06 ± 32.64
0.6
0.586
0.001
<0.001
<0.001
<0.001
<0.001
0.043
0.052
0.301
0.108
0.913
0.006
0.03
Applying CRT eligibility ECHO criteria to the data [those with interventricular dyssynchrony 
>55msec, intraventricular dyssynchrony >65msec, interventricular mechanical delay > 40msec, Aortic 
pre ejection delay >140msec and septum to posterior wall delay > 130msec] there were 9 individuals in 
the low EF group and 1 in the normal EF group who had dyssynchrony and would benefit from 
CRT( Table III)
Table III
ELIGIBLE FOR CRT 
BY ECHO CRITERIA
NOT ELIGIBLE FOR CRT 
BY ECHO CRITERIA
TOTAL
Low EF 9 29 38
Normal EF 1 30 31
Total 10 59 69
Table IV
COMPARING THE ECG CRITERIA [QRS >140 MSEC] WITH ECHO CRITERIA FOR DYSSYNCHRONY
 ECHO
ABNORMAL CASES NORMAL CASES TOTAL
QRS DURATION       >=140
ON ECG                     <140(NORMAL-ECG)
                                   TOTAL
8
1
9
12
17
29
20
18
38
Sensitivity = 88.9%,  specificity = 41.4%
Positive predictive value = 32%,  negative predictive value = 92%
Prevalence = 24% , kappa = 0.188
Only 18% agreement beyond chance, between ECG and ECHO in diagnosing dyssynchrony
Table V
THE ISOVOLUMIC CONTRACTION TIME WAS GREATER FOR THOSE WITH LOW EJECTION FRACTION IN ALL SEGMENTS 
(HOWEVER IT WAS NOT STATISTICALLY SIGNIFICANT)
ISOVOLUMIC CONTRA 
CTION TIME(PCTm)
EJECTION 
FRACTION
N MEAN STD. 
DEVIATION
STD. ERROR 
MEAN
P Value
Q to RV Lateral           <=50 
>50
38 
31
57.89 
58.61
21.76 
32.33
3.53 
5.81 .91
Q to Basal Septal            <=50 
>50
38 
31
79.13 
65.55
33.93 
35.09
5.50 
6.30 .11
Q to Basal anterior <=50 
>50
38 
31
97.71 
79.61
37.64 
37.83
6.11 
6.79 0.05
Q to Basal inferior <=50 
>50
38 
31
83.03 
73.23
41.21 
35.72
6.68 
6.42 0.3
Table VI
T-TEST SHOWING SIGNIFICANT DIFFERENCE IN THE PCTm  FOR THE BASAL LATERAL SEGMENT OF THE LV BETWEEN THE 
LOW AND NORMAL EF GROUPS (P=0.04)
EJECTION FRACTION N MEAN STD. DEVIATION STD. ERROR MEAN
Q to Basal     <=50 
Lateral           >50
38 
31
127.03 
103.16
49.41 
46.01
8.02 
8.26
THE LV BASAL LATERAL SEGMENT HAD DELAYED CONTRACTION COMPARED TO ALL OTHER SEGMENTS 
0 20 40 60 80 100 120 140
RV LATERAL
SEPTAL
LV INFERIOR
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NORMAL EF
LOW EF
Table VII
IN THE LOW EF GROUP THE LV BASAL LATERAL SEGMENT IS SIGNIFICANTLY DELAYED COMPARED TO ALL THE OTHER 
BASAL SEGMENTS 
Basal Segment N Mean Std. Deviation Std. Error 95% Confidence Interval for Mean
Upper Bound Lower Bound
RV 
Sep 
Lat 
Ant 
Inf 
Total
38 
38 
38 
38 
38 
190
57.89 
79.13 
127.03       97.71 
83.03         88.96
21.76           33.93 
49.41 
37.64 
41.21           43.96
3.53 
5.50 
8.01 
6.10 
6.68 
3.19
50.74 
67.98 
110.79 
85.34 
69.48 
82.67
65.05 
90.28 
143.27 
110.08 
96.57 
95.25
RV - Right ventricle free wall ; Sep - Septum ; Lat - Lateral ; Ant - Anterior ; Inf – Inferior 
Table VIII
COMPARING DYSSYNCHRONY BETWEEN VARIOUS SEGMENTS IN LOW EF GROUP
Basal Segment Mean Difference Std. Error Sig. 95% Confidence Interval for Mean
Lower bound Upper Bound
PCTm (msec)
Fig 10
RV                          Sep
        Lat
         Ant
        Inf 
-21.24
-69.13*
-39.82*
-25.13*
8.69
8.69
8.69
8.69
.155
.000
.000
.043
-45.94
-93.83
-64.52
-49.83
3.46
-44.43
-15.12
-0.43
Sep                          RV
                                Lat
          Ant
        Inf 
21.24
-47.89*
-18.58
-3.89
8.69
8.69
8.69
8.69
.155
.000
.339
1.000
-3.46
-72.59
-43.28
-28.59
45.94
-23.20
6.12
20.80
Lat                          RV 
       Sep
       Ant
                               Inf 
69.13*
47.89*
29.32*
44.00*
8.69
8.69
8.69
8.69
.000
.000
.009
.000
44.43
23.20
4.61
19.30
93.83
72.59
54.02
68.70
Ant                         RV
                               Sep
                               Lat
                               Inf 
39.82*
18.58
-29.32*
14.68
8.69
8.69
8.69
8.69
.000
.339
.009
.929
15.12
-6.12
-54.01
-10.01
64.52
43.28
-4.62
39.38
Inf                          RV
       Sep
      Lat
                              Ant
25.13*
3.89
-44.00*
-14.68
8.69
8.69
8.69
8.69
.043
1.000
.000
.929
.43
-20.80
-68.70
-39.38
49.83
28.59
-19.30
10.02
* The mean difference is significant at the .05 level
Table IX
IN THE NORMAL EF GROUP THE LV BASAL LATERAL SEGMENT IS DELAYED WHEN COMPARED TO THE BASAL SEPTAL, 
BASAL INFERIOR AND RV BASAL LATERAL SEGMENT
 N Mean Std. Deviation Std. Error 95% Confidence Interval for Mean
Upper Bound Lower Bound
RV
Sep
Lat
Ant
Inf 
Total
31
31
31
31
31
155
58.61
65.55
103.16
79.61
73.23
76.03
32.33
35.09
46.01
37.82
35.72
40.23
5.80
6.30
8.26
6.79
6.41
3.23
46.75
52.68
86.28
65.74
60.12
69.65
70.47
78.42
120.04
93.49
86.33
82.42
Table X
COMPARING DYSSYNCHRONY BETWEEN VARIOUS SEGMENTS IN NORMAL EF GROUP
Basal Segment Mean Difference Std. Error Sig. 95% Confidence Interval for Mean
Lower bound Upper Bound
RV                           Sep
          Lat
          Ant
         Inf 
-6.93
-44.55
-21.00
-14.61
9.57
9.57
9.57
9.57
1.00
.00
.298
1.00
-34.21
-71.82
-48.27
-48.88
20.34
-17.28
6.27
12.66
Se                            RV
         Lat
         Ant
        Inf 
6.93
-37.61
-14.06
-7.68
9.57
9.57
9.57
9.57
1.00
.001
1.00
1.00
-20.33
-64.88
-41.33
-34.94
34.20
-10.34
13.20
19.39
Lat                          RV 
       Se
       Ant
       Inf 
44.55
37.61
23.55
29.93
9.57
9.57
9.57
9.57
.000
.001
.150
.021
17.28
10.34
-3.72
2.66
71.81
64.88
50.81
57.20
Ant                         RV 21.00 9.57 .298 -6.27 48.27
                               Se
      Lat
                               Inf 
14.06
-23.55
6.39
9.57
9.57
9.57
1.00
.150
1.00
-13.20
-50.81
-20.89
41.33
3.72
33.66
Inf                          RV 
     Se
      Lat
      Ant
14.61
7.68
-29.93
-6.39
9.57
9.57
9.57
9.57
1.00
1.00
.021
1.00
-12.66
-19.59
-57.20
-33.66
41.88
34.95
-2.66
20.88
Table XI
COMPARING THE INTRAVENTRICULAR MYOCARDIAL ACTIVATION DELAY BETWEEN THE LOW AND NORMAL EF GROUPS 
SHOWING A SIGNIFICANTLY GREATER DELAY IN THE LOW EF GROUP (P = 0.03)
EJECTION FRACTION N MEAN STD. DEVIATION STD. ERROR MEAN
LV Dyssynchrony  <=50
                                >50
38
31
68.82
47.06
40.69
32.64
6.60
5.87
Table XII
COMPARING THE INTERVENTRICULAR MYOCARDIAL ACTIVATION DELAY BETWEEN THE LOW AND NORMAL EF GROUPS 
SHOWING A SIGNIFICANTLY GREATER DELAY IN THE LOW EF GROUP (P = 0.008)
RVLV DELAY
NORMAL ABNORMAL
TOTAL
Low EF 13 25 38
Normal EF 21 10 31
Total 34 35 69
Table XIII
THE INTERVENTRICULAR MECHANICAL DELAY IS SIGNIFICANTLY GREATER FOR THE LOW EF GROUP THAN THE NORMAL 
EF GROUP (P=0.008)
INTERVENTRICULAR MECHANICAL DELAY
NORMAL ABNORMAL
TOTAL
Low EF 11 27 38
Normal EF 19 12 31
Total 30 39 69
Table XIV
THE AORTIC PREEJECTION DELAY IS SIGNIFICANTLY GREATER FOR THE LOW EF GROUP THAN THE NORMAL EF GROUP 
(P=0.003)
AORTIC PRE EJECTION DELAY
NORMAL ABNORMAL
TOTAL
Low EF 8 30 38
Normal EF 18 13 31
Total 26 43 69
Table XV
THERE IS NO SIGNIFICANT DIFFERENCE BETWEEN THE SEPTUM TO POSTERIOR WALL MOTION DELAY BETWEEN THE LOW 
AND NORMAL EF GROUPS (P=0.124)
SEPTUM TO POSTERIOR WALL MOTION 
DELAY
NORMAL ABNORMAL
TOTAL
Low EF 22 16 38
Normal EF 24 7 31
Total 46 23 69
Table XVI
A CUT OFF POINT OF INTERVENTRICULAR DELAY >48.5 msec 
Coordinates of the Curve
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Table XVII
MULTIVARIATE LINEAR REGRESSION ANALYSIS SHOWING LVIDd , EF AND QRS DURATION BEING THE ONLY INDEPENDENT 
DETERMINANTS OF RVLV DELAY
VARIABLE ß COEEFICIENT P VALUE
95% CONFIDENCE INTERVAL
LOWER BOUND UPPER BOUND
Dyspnea
Diabetes
Pulse Rate
TR Severity
QRS Duration
EF Value
7.4
2.08
.452
2.5
.753
-1.05
.57
.84
.141
.67
0.02
.015
-18.77
-19.27
-0.154
-9.33
.121
-1.9
33.60
23.43
1.059
14.48
1.38
-0.21
     
 SCATTER PLOT SHOWING THAT INERVENTRICULAR DYSSYNCHRONY IS INVERSELY RELATED TO  THE EJECTION 
FRACTION
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SCATTER PLOT SHOWING THAT INTERVENTRICULAR DYSSYNCHRONY IS DIRECTLY RELATED TO THE LV 
INTERNAL DIAMETER IN DIASTOLE 
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DISCUSSION
The present study demonstrates the usefulness of Tissue Doppler in analyzing patterns of myocardial 
systolic activation of both left and right ventricle in patients with LBBB. To the best of our knowledge, 
this is the first Indian report comparing regional systolic dyssynchrony between patients with LBBB 
with either normal or impaired LV global systolic function.
In our study protocol, we evaluated three useful indices of interventricular delay in patients with 
LBBB: 
(1) QRS width by surface ECG
(2) (Q-Ao)-(Q-Pulm) by standard echo- Doppler [IVMD];
(3) InterVentricular Delay by TDI. 
ECG, Doppler and TDI assessment :
 The IVMD and interventricular delay by TDI were significantly more in those patients with 
LBBB who had low EF proving beyond doubt that of LBBB patients those with low EF had greater 
interventricular dyssynchrony. The qrs width was also significantly greater in those patients with 
LBBB who had a low EF. However it was not found to correlate well with the ECHO parameters 
evaluating dyssynchrony. In fact, no significant correlation was observed (Pearson correlation of 0.374) 
between TDI Interventricular delay and qrs duration. This result confirms that, despite similar qrs 
morphology, patients with CHF and LBBB may present heterogeneities of myocardial 
electromechanical coupling and different locations of mechanical dyssynchrony consequent to 
myocardial disease or subendocardial ischemia. There was only a 18% agreement beyond chance 
between ECG [qrsd >140msec] and Echo criteria in selecting patients for CRT. Though the ECG was 
reasonably sensitive it was far less specific in identifying patients with dyssynchrony. Thus Tissue 
Doppler Echo will help us in better selection of those cases that would benefit most from CRT.
TDI – to measure  intraventricular dyssynchrony  :
         In our study intraventricular dyssynchrony as assessed by M mode echo - septum to posterior wall 
motion delay was not significantly different between the low and normal EF groups. Our results are 
consistent with published literature suggesting that it is a measurement associated with a lot of 
subjective error and hence may be regarded as an unreliable method to assess intraventricular 
dyssynchrony.47           
 Tissue Doppler assessment of intraventricular dyssynchrony showed there was significantly longer 
isovolumic contraction time to the LV basal lateral wall in patients with LBBB. This delay was much 
longer in those with low EF when compared to those with normal EF. The shortest and the longest 
ICTm were measured in the basal septal and lateral segments, respectively, thus resulting in 43 msec of 
delay between the LV septum and lateral wall. This data diverts from the normal, in the sense that the 
last segment to contract is the basal lateral, whereas it is the posterior segment in normal subjects. 
Normally, LV contraction occurs without significant delay almost simultaneously in every LV segment 
that results in synchronous contraction.36 However, in patients with LBBB, contraction is delayed far 
more than the normal range. 
TDI –RV basal lateral to LV basal lateral :
               In patients with LBBB there was a marked difference in the RV basal free wall to LV basal 
lateral wall in both the low and normal EF groups. This suggests that all patients with LBBB have 
some amount of inter and intraventricular dyssynchrony, those with low ejection fraction having 
greater dyssynchrony. These findings translated to a greater number of individuals with lower ejection 
fraction satisfying the echo criteria for cardiac resynchronization therapy; 9 out of 38 as against 1 out 
of 31 with normal ejection fraction. This suggests that in LBBB patients significant dyssynchrony 
could occur though it is much less frequent in those with normal ejection fraction.
       
In individuals with LBBB, the uncoordinated systole worsens the workload and the stress of the left 
ventricle. The interventricular septum, which is usually activated first, develops a small pressure load 
with low wall stress, and contributes minimally to intraventricular pressure increase. On the other hand, 
the LV lateral free wall is activated late, has a high presystolic stress, and is therefore affected by 
unbalanced load and stress. The final result is a worsening of LV global work with, with prolongation 
of presystolic ventricular time (i.e, PCTm), delay in the onset of LV systole, shortening of LV ejection 
and filling time, and further depression of LV ejection fraction.                        
Multivariate analysis provided further information about this association by adjusting for several 
confounders, chosen according to the heart physiology and the presence of intraventricular conduction 
abnormalities. By this model, LV dilatation, ejection fraction and qrs duration were the only 
independent determinants of TDI InterVentricular delay. In addition, an InterVentricular delay >48.5 
msec (a cut-off value selected by ROC curve analysis) identified patients with impaired LV global 
systolic function with a sensitivity of 71% and specificity of 65%.
Why TDI is better? :
Our findings are consistent with several recent reports emphasizing the usefulness of TDI to support 
cardiac resynchronization therapy in patients with severe CHF and LBBB. In particular, as reported by 
Ansalone et al 46, the extent of myocardium with asynchronous contraction at the LV base predicted the 
improvement in LV systolic performance and reversion of LV remodeling during short- and long-term 
biventricular pacing. Furthermore, individual tailoring of the pacing site, with accurate preactivation of 
myocardial regions showing mechanical dyssynchrony, produced a significant reduction of the extent 
of InterVentricular delay, and consequent significant improvement of LV EF%. In other words, the 
delayed longitudinal contraction assessed by TDI represents mechanical LV dyssynchrony and thus a 
contractile reserve, which can be recruited by means of optimized cardiac resynchronization therapy It 
was also shown that after CRT, the delay between the contraction of septal and lateral walls was 
diminished. CRT improves coordination of contraction among LV segments due to homogeneous 
activation and serves to restore synchronous contraction. TDI enables the quantification of systolic and 
diastolic functions of separate LV segments and thus help us in appropriately planning the position of 
the coronary sinus lead and timing the activation of the different myocardial segments.
Study limitations : 
1. The major limitation of our study is the Doppler technique used. It is angle dependent.
Also there is the possible presence of artifacts. However we tried to overcome this by taking a 
minimum of 3 measurements for each parameter and calculating an average of the same.
2. Sample size :The number of subjects studied is only 69. A larger study needs to be done to confirm 
our findings.
                            
                                        CONCLUSIONS
                                    The main findings of our study are 
1) The criteria for cardiac resynchronization therapy was satisfied by 9 out of 38 patients
 with LBBB on baseline ECG and low ejection fraction on Echo. 
2) The prevalence of cardiac dyssynchrony in patients with LBBB on baseline 
ECG and LV dysfunction was 23.6%.
3) The prevalence of cardiac dyssynchrony in patients with LBBB on baseline 
ECG and normal LV function was 0.03%.
4) Patients with LBBB and low ejection fraction had greater dyssynchrony than those 
with LBBB and normal ejection fraction .
5). Tissue Doppler is a better technique than ECG in detecting dyssynchrony.
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ANNEXURE
T-TEST : AGE DISTRIBUTION VERSUS EJECTION FRACTION – NO SIGNIFICANT 
DIFFERENCE (P=0.6)
N MEAN STD. DEVIATION STD. ERROR MEAN
Age        low EF
               Normal EF
38
31
57.50
59.03
12.483
11.580
2.025
2.080
SEX DISTRIBUTION 
FREQUENCY PERCENT
Valid        Female
                 Male
                Total
25
44
69
36.2
63.8
100.0
SEX VERSUS EJECTION FRACTION- NO SIGNIFICANT DIFFERENCE (P=1)
Female male TOTAL
Low EF 14 24 38
Normal EF 11 20 31
Total 25 44 69
PRESENCE OF Thyroid dysfunction AMONG SUBJECTS
FREQUENCY PERCENT
                 Euthyroid
                 Hypothyroid
                 Hyperthyroid
                 Total
56
10
3
69
81.2
14.5
4.3
100.0
DISTRIBUTION OF DIABETES AMONG PATIENTS
FREQUENCY PERCENT
 Diabetes       Absent
                      Present
                     Total
25
44
69
36.2
63.8
100.0
DISTRIBUTION OF HYPERTENSION AMONG PATIENTS
FREQUENCY PERCENT
 Hypertension       Absent
                             Present
                             Total
28
41
69
40.6
59.4
100.0
DISTRIBUTION OF DYSLIPIDEMIA AMONG PATIENTS
FREQUENCY PERCENT
 Dyslipidemia      Absent
                             Present
                             Total
20
49
69
29
71
100.0
DISTRIBUTION OF ISCHEMIC HEART DISEASE AMONG PATIENTS
FREQUENCY PERCENT
 IHD                     Absent
                             Present
                             Total
44
25
69
63.8
36.2
100.0
DISTRIBUTION OF SMOKING AMONG PATIENTS
FREQUENCY PERCENT
 Smoking              No
                             Yes
                             Total
50
19
69
72.5
27.5
100.0
DISTRIBUTION OF ALCOHOL CONSUMPTION AMONG PATIENTS
FREQUENCY PERCENT
 Alcohol Consumption   No
                                       Yes
                                       Total
64
5
69
92.8
7.2
100.0
Correlation between QRS duration and all other parameters
TABLE THAT SHOWS A SIGNIFICANT DIFFERENCE IN THE QRS DURATION BETWEEN THE LOW AND NORMAL EJECTION 
FRACTION GROUPS (P=0.001) WITH NO SIGNIFICANT DIFFERENCE IN THE PULSE RATE (P=0.58)
ejection fraction n mean std. deviation std. error
mean
QRS  Values                   Low EF
                                        Normal EF
38
31
148.53
135.71
18.557
11.725
3.010
2.106
Pulse Rate                      Low EF
                                       Normal EF
38
31
84.82
82.58
15.123
18.768
2.453
3.371
T-TEST: SIGNIFICANT DIFFERENCE BETWEEN THE LVIDD IN THE LOW AND NORMAL 
EF GROUPS (P<0.001)
1 -.351** .355** .337** .374** .365** .496**
.003 .003 .005 .002 .002 .000
69 69 69 69 69 69 69
-.351** 1 -.451** -.281* -.293* -.290* -.242*
.003 .000 .019 .015 .016 .045
69 69 69 69 69 69 69
.355** -.451** 1 .624** .354** .422** .437**
.003 .000 .000 .003 .000 .000
69 69 69 69 69 69 69
.337** -.281* .624** 1 .238* .193 .389**
.005 .019 .000 .049 .111 .001
69 69 69 69 69 69 69
.374** -.293* .354** .238* 1 .867** .302*
.002 .015 .003 .049 .000 .012
69 69 69 69 69 69 69
.365** -.290* .422** .193 .867** 1 .334**
.002 .016 .000 .111 .000 .005
69 69 69 69 69 69 69
.496** -.242* .437** .389** .302* .334** 1
.000 .045 .000 .001 .012 .005
69 69 69 69 69 69 69
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
QRSvalues
EF Value
Aortic Preejection Delay
Inter ventricular
Mechanical Delay
RVLV Delay
LV Dyssynchrony
Septum to Posterior
wall motion Delay
QRSvalues EF Value
Aortic
Preejection
Delay
Inter
ventricular
Mechanical
Delay RVLV Delay
LV
Dyssynchrony
Septum to
Posterior wall
motion Delay
Correlation is significant at the 0.01 level (2-tailed).**. 
Correlation is significant at the 0.05 level (2-tailed).*. 
EJECTION FRACTION N MEAN STD. 
DEVIATION
STD. ERROR
MEAN
LVIDD Value                 <=50
                                        >50
38
31
62.68
48.35
9.355
5.919
1.518
1.063
 
T-TEST: SIGNIFICANT DIFFERENCE BETWEEN THE LVIDS IN THE LOW AND NORMAL    EF groups (p<0.001)
EJECTION FRACTION N MEAN STD. 
DEVIATION
STD. ERROR
MEAN
LVIDS Value                 <=50
                                        >50
38
31
51.50
35.52
8.773
9.327
1.423
1.675
T-TEST: SIGNIFICANT DIFFERENCE BETWEEN THE EDV , ESV  IN THE LOW AND 
NORMAL EF GROUPS (P<0.001)
EJECTION FRACTION N MEAN STD. 
DEVIATION
STD. ERROR
MEAN
EDV  Value                  <=50
                                      >50
38
31
188.97
108.39
59.892
30.177
9.716
5.420
ESV Value                    <=50
                                       >50     
38
31
126.05
47.35
51.607
13.502
8.372
2.425
MEAN VALUES OF ISOVOLUMIC CONTRACTION TIMES IN ALL SEGMENTS
CORRELATIONS BETWEEN VARIOUS ECHO INDICES SHOWING A STRONG CORRELATION BETWEEN INTER AND 
INTRAVENTRICULAR DYSSYNCHRONY
69 0 160 58.22 3.23 26.811
69 10 180 73.03 4.20 34.869
69 47 220 116.30 5.90 49.044
69 30 187 89.58 4.64
38.52669 0 200 78.62 4.68 38.870
Q to RV Lateral
Q to Basal Septal
Q to Basal Lateral
Q to Basal anterior
Q to Basal inferior
Statistic Statistic Statistic Statistic Std. Error Deviation
N Minimum Maximum Mean Std.
Correlations
1 .872** .874** .850** -.719** .472** .355** .359**
.000 .000 .000 .000 .000 .003 .002
69 69 69 69 69 69 69 69
.872** 1 .792** .798** -.732** .398** .263* .269*
.000 .000 .000 .000 .001 .029 .025
69 69 69 69 69 69 69 69
.874** .792** 1 .960** -.712** .398** .356** .407**
.000 .000 .000 .000 .001 .003 .001
69 69 69 69 69 69 69 69
.850** .798** .960** 1 -.819** .418** .316** .369**
.000 .000 .000 .000 .000 .008 .002
69 69 69 69 69 69 69 69
-.719** -.732** -.712** -.819** 1 -.351** -.293* -.290*
.000 .000 .000 .000 .003 .015 .016
69 69 69 69 69 69 69 69
.472** .398** .398** .418** -.351** 1 .374** .365**
.000 .001 .001 .000 .003 .002 .002
69 69 69 69 69 69 69 69
.355** .263* .356** .316** -.293* .374** 1 .867**
.003 .029 .003 .008 .015 .002 .000
69 69 69 69 69 69 69 69
.359** .269* .407** .369** -.290* .365** .867** 1
.002 .025 .001 .002 .016 .002 .000
69 69 69 69 69 69 69 69
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
LVIDD Value
LVIDS Value
EDV Value
ESV Value
EF Value
QRSvalues
RVLV Delay
LV Dyssynchrony
LVIDD Value LVIDS Value EDV Value ESV Value EF Value QRSvalues RVLV Delay
LV
Dyssynchrony
Correlation is significant at the 0.01 level (2-tailed).**. 
Correlation is significant at the 0.05 level (2-tailed).*. 

MASTER SHEET
SNO Name Hno Age sex NYHA D CP P Fatigue Abd_dis Thy_dys HT
1 Abdul Bareque Ahmed     615067C 50 1 3 1 0 0 1 0 0 1
2 Almas Begum             59346 71 0 1 1 1 0 0 0 0 1
3 Amulya                  778468C 60 1 2 1 0 0 1 0 0 0
4 Amulya Ratan Paul       793950C 65 1 3 1 1 0 1 1 0 1
5 Ananda Kumar Biswas     784931C 78 1 1 1 1 1 0 0 1 1
6 Armugam                 613046C 65 1 1 0 0 0 0 0 0 1
7 Arunachalam             811874C 62 1 3 1 1 0 1 0 0 0
8 Bharathi Bhowmick       656204C 53 0 1 1 0 0 0 0 1 0
9 Bimma Devi              648574C 63 0 2 1 1 0 1 0 0 0
10 Biswanath Chakraborthy  780305C 61 1 2 1 0 0 1 0 0 1
11 Chandra Babu            604888C 45 1 2 1 0 0 0 0 0 0
12 Deb Kumar Naskar        752592C 50 1 2 0 0 0 1 0 0 1
13 Dhandapani              764770C 62 1 4 1 0 0 1 0 0 1
14 Dolly Mithra            815352C 48 0 2 1 1 0 0 0 0 1
15 Durvasalu               836608C 83 1 3 1 0 0 0 0 0 0
16 Fazley Pauman           827378C 55 1 3 1 1 0 0 0 0 0
17 Ganesh Chandra Munnerje 811536C 75 1 1 0 0 0 1 0 1 1
18 Hanif Ansari            833721C 64 1 3 1 1 0 0 0 0 0
19 Harikrishnan            046099B 53 1 1 1 0 0 0 0 0 1
20 Hasna Hena Begum        559048C 49 0 2 1 1 0 0 0 0 1
21 Jinhuri Banerjee        781503C 80 1 2 1 0 0 0 0 2 1
22 Kanai Lal Giri          795826C 49 1 2 1 0 0 0 1 0 0
23 Lily Pushpam            770818C 62 0 1 0 0 0 0 0 0 1
24 M.Vedham                808691C 66 0 3 1 0 0 1 0 1 1
25 Mahalingam              179525C 52 1 1 0 0 0 0 0 0 1
26 Manglal Majui           283500B 58 1 2 0 1 0 0 0 0 1
27 Manimegalai             368822C 65 0 4 1 0 0 1 0 2 0
28 Mrinal Kanti            840005C 44 1 1 0 1 0 0 0 0 0
29 Mriwal Kanti            834970C 65 1 2 1 0 0 0 0 0 1
30 Mumzedar                805106C 60 1 2 1 0 0 0 0 0 1
31 Munnirisuna             771665C 23 1 2 0 0 1 1 0 2 0
32 Nabendu Shekar          820548C 63 1 1 1 0 0 0 0 0 1
33 Netaj ChandraSarkar     793961C 54 1 2 1 0 0 0 0 0 0
34 Panchalai               826738C 65 0 2 1 1 0 0 0 0 1
SNO Name Hno DM DL IHD Sm Al pulse BP JVP S3 S4
1 Abdul Bareque Ahmed     615067C 1 1 1 0 0 80 110/60  1 1 0
2 Almas Begum             59346 0 1 1 0 0 100 170/80  0 1 0
3 Amulya                  778468C 1 1 1 1 1 89 140/80  0 0 0
4 Amulya Ratan Paul       793950C 0 1 0 0 0 106 110/80  1 1 0
5 Ananda Kumar Biswas     784931C 1 1 1 0 0 70 130/90  0 1 1
6 Armugam                 613046C 0 0 0 0 0 100 136/90  0 1 0
7 Arunachalam             811874C 1 0 1 1 1 85 100/60  0 1 0
8 Bharathi Bhowmick       656204C 1 1 0 0 0 72 100/70  0 0 1
9 Bimma Devi              648574C 1 1 1 0 0 84 102/60  0 0 0
10 Biswanath Chakraborthy  780305C 1 1 1 1 0 80 120/80  0 1 0
11 Chandra Babu            604888C 1 1 0 1 0 94 102/72  1 1 0
12 Deb Kumar Naskar        752592C 1 1 0 1 0 84 120/70  0 0 0
13 Dhandapani              764770C 0 1 0 0 0 80 90/60   1 1 0
14 Dolly Mithra            815352C 1 1 0 0 0 70 150/70  0 1 0
15 Durvasalu               836608C 0 0 0 1 0 97 110/70  0 0 0
16 Fazley Pauman           827378C 0 1 1 1 0 69 120/70  0 0 0
17 Ganesh Chandra Munnerje 811536C 1 1 1 1 0 56 140/80  0 0 1
18 Hanif Ansari            833721C 0 1 1 0 0 75 100/70  0 0 0
19 Harikrishnan            046099B 1 1 0 0 0 60 160/90  0 0 0
20 Hasna Hena Begum        559048C 1 1 0 0 0 80 140/80  0 1 0
21 Jinhuri Banerjee        781503C 1 1 0 1 0 65 110/70  0 0 1
22 Kanai Lal Giri          795826C 1 0 0 0 0 50 110/80  1 0 0
23 Lily Pushpam            770818C 0 0 0 0 0 65 130/80  0 0 1
24 M.Vedham                808691C 1 1 1 0 0 86 120/70  1 1 0
Name Hno Age sex NYHA D CP P Fatigue Abd_dis Thy_dys HT
Poraiappan              791244C 60 1 2 1 1 0 1 0 0 0
Pown                    780423C 56 0 2 0 0 0 1 0 0 1
Prabir Kumar Biswas     778635C 51 1 2 0 1 0 1 0 0 1
Prabodh Chandra Garai   344077C 46 1 1 1 1 0 0 0 0 1
Pradip Kumar            786171C 48 1 2 1 1 1 1 0 1 0
Purushothaman           291720C 65 1 2 1 1 0 1 0 0 0
Ragavan                 470842C 64 1 3 1 0 0 0 0 0 1
Rai                     773873C 58 1 1 1 0 0 1 0 0 0
Rajalakshmi             939143B 65 0 4 1 0 0 1 0 0 1
Rama                    834511C 31 0 2 1 1 0 0 0 1 1
Ramakani Mishra         819686C 53 1 1 1 0 0 0 0 0 0
Ramanath Maity          596897C 63 1 2 1 0 1 1 0 0 0
Ramasurey Prasad        793747C 71 1 2 1 0 0 1 0 1 0
Ramchandra Phasai       794249C 52 1 3 1 0 1 1 0 0 0
Ranu Mitra              830777C 54 0 1 0 0 0 0 0 1 1
Ratan Ghosh             737499C 40 1 3 1 0 0 0 0 0 1
Ruckmani                016357C 54 0 2 1 0 0 0 0 0 1
Sabanti Saha            083349C 30 0 1 1 0 1 0 0 0 0
Sankarlal Dey           797360C 67 1 3 1 1 0 1 1 0 1
Saroja                  815512C 75 0 2 0 1 0 0 0 1 0
Selvaraj                837975C 48 1 2 1 0 0 1 0 0 1
Shika Rani Chaki        313338B 61 0 3 1 0 0 0 0 0 1
Sisir Kumar Chakraborth 784071C 62 1 2 1 1 1 0 0 0 1
Sita Pyakurec           796030C 68 0 2 1 1 1 1 0 0 1
Subramani               824506C 62 1 3 1 0 0 0 0 0 1
Suchitra                394231C 35 0 2 1 0 1 0 0 0 1
Sulaja 829445C 65 0 2 1 1 0 0 0 0 1
Susama                  740380C 67 0 2 1 0 1 0 0 1 1
Swapan Kumar            807934C 45 1 2 1 0 0 0 0 0 0
Tek Bahaduk Singh       731552C 69 1 1 1 0 0 0 0 0 1
Thajunnisa              866887B 60 0 3 1 0 1 1 0 0 0
Thomas                  636360C 61 1 1 0 0 0 0 0 0 0
Vanitha                 828803C 37 0 3 1 0 0 0 0 0 0
Vasantha                180463B 74 0 3 1 0 0 0 0 0 0
Veddaponnammal          749961A 80 0 4 1 1 0 0 0 0 1
Name Hno DM DL IHD Sm Al pulse BP JVP S3 S4
Poraiappan              791244C 1 0 1 0 0 84 110/70  0 0 0
Pown                    780423C 1 1 0 0 0 63 140/90  0 0 1
Prabir Kumar Biswas     778635C 0 0 0 0 1 70 210/120 0 0 1
Prabodh Chandra Garai   344077C 0 1 0 0 0 78 130/80  0 0 0
Pradip Kumar            786171C 1 0 1 1 0 62 140/90  0 0 0
Purushothaman           291720C 0 1 0 0 0 105 110/70  0 0 1
Ragavan                 470842C 0 0 0 0 0 100 140/80  1 0 1
Rai                     773873C 1 1 0 1 0 79 160/80  0 0 0
Rajalakshmi             939143B 0 1 0 0 0 126 80/60   1 1 0
Rama                    834511C 1 1 1 0 0 80 130/80  0 0 0
Ramakani Mishra         819686C 1 1 1 1 0 82 110/70  0 0 1
Ramanath Maity          596897C 1 1 1 1 0 110 140/90  0 0 0
Ramasurey Prasad        793747C 1 1 0 1 0 89 150/100 0 0 0
Ramchandra Phasai       794249C 1 1 0 0 0 100 100/70  0 1 0
Ranu Mitra              830777C 1 1 0 0 0 113 190/90  0 0 0
Ratan Ghosh             737499C 1 0 0 0 0 88 140/80  1 1 0
Ruckmani                016357C 1 1 1 0 0 76 150/100 0 1 0
Sabanti Saha            083349C 0 0 0 0 0 84 120/80  0 0 0
Sankarlal Dey           797360C 1 1 0 1 0 93 110/60  0 0 0
Saroja                  815512C 0 1 0 0 0 105 110/80  0 0 1
Selvaraj                837975C 1 1 1 0 0 102 140/80  0 0 0
Shika Rani Chaki        313338B 1 1 0 0 0 75 160/90  0 0 1
Sisir Kumar Chakraborth 784071C 1 1 0 0 0 88 140/80  0 0 1
Sita Pyakurec           796030C 0 1 1 0 0 78 130/90  0 0 0
Subramani               824506C 1 1 1 1 0 76 190/100 0 0 1
Suchitra                394231C 0 0 0 0 0 82 150/80  0 0 0
Sulaja 829445C 1 1 0 0 0 81 150/70  0 0 0
Susama                  740380C 0 1 0 0 0 140 150/102 0 1 0
Swapan Kumar            807934C 0 1 0 0 0 66 110/85  1 0 1
Tek Bahaduk Singh       731552C 1 1 0 0 0 81 180/98  0 0 0
Thajunnisa              866887B 1 0 0 0 0 81 130/80  1 1 0
Thomas                  636360C 1 1 0 1 0 100 120/80  0 0 1
Vanitha                 828803C 0 0 0 0 0 78 100/70  1 1 0
Vasantha                180463B 1 1 0 0 0 64 110/68  0 0 0
Veddaponnammal          749961A 1 0 1 0 0 96 100/70  1 1 0
Name Hno QRS LVIDD LVIDS EDV ESV EF MR TR AR APED
Poraiappan              791244C 140 46 33 97 39 58 0 0 0 170
Pown                    780423C 122 47 34 98 41 57 1 0 1 130
Prabir Kumar Biswas     778635C 144 48 33 99 43 56 0 0 0 133
Prabodh Chandra Garai   344077C 136 55 41 147 63 53 0 0 0 153
Pradip Kumar            786171C 133 61 55 185 121 35 2 1 0 130
Purushothaman           291720C 149 48 35 106 51 52 3 3 1 170
Ragavan                 470842C 140 47 39 104 66 37 2 1 0 140
Rai                     773873C 131 47 33 127 60 53 0 0 0 173
Rajalakshmi             939143B 149 82 68 260 174 33 3 2 0 160
Rama                    834511C 124 43 29 82 34 57 0 0 0 153
Ramakani Mishra         819686C 156 70 57 179 103 42 3 3 1 155
Ramanath Maity          596897C 158 54 44 144 74 36 0 0 0 160
Ramasurey Prasad        793747C 136 49 34 128 51 59 0 0 0 153
Ramchandra Phasai       794249C 150 70 60 255 180 30 3 0 0 190
Ranu Mitra              830777C 151 58 41 165 74 55 1 0 0 120
Ratan Ghosh             737499C 150 53 43 123 81 34 0 2 0 160
Ruckmani                016357C 125 40 20 58 26 54 0 0 0 133
Sabanti Saha            083349C 154 59 46 177 97 45 2 1 0 170
Sankarlal Dey           797360C 124 46 33 99 44 56 0 0 0 150
Saroja                  815512C 139 46 33 99 43 56 0 0 0 153
Selvaraj                837975C 128 58 42 105 80 24 0 0 0 93
Shika Rani Chaki        313338B 134 59 46 150 97 35 2 1 0 147
Sisir Kumar Chakraborth 784071C 122 66 55 221 151 32 3 1 0 120
Sita Pyakurec           796030C 141 55 45 149 93 38 3 0 0 200
Subramani               824506C 164 67 53 159 60 62 0 0 0 50
Suchitra                394231C 131 46 32 96 40 58 1 0 0 160
Sulaja 829445C 125 41 29 76 31 59 0 0 0 107
Susama                  740380C 133 46 33 97 44 55 2 0 0 153
Swapan Kumar            807934C 162 68 57 221 147 33 0 0 0 190
Tek Bahaduk Singh       731552C 157 57 47 198 125 37 1 0 1 170
Thajunnisa              866887B 160 74 62 219 146 33 3 2 0 207
Thomas                  636360C 158 51 33 63 28 58 0 0 0 153
Vanitha                 828803C 136 56 48 155 106 32 2 2 0 167
Vasantha                180463B 150 70 56 259 154 40 3 0 0 180
Veddaponnammal          749961A 152 41 34 143 106 40 3 0 3 160
Name Hno PPED IVMD SPMD Qrl Qbs Qbl Qba Qbi RVLV LV DYS
Poraiappan              791244C 113 57 280 30 40 100 30 110 70 70
Pown                    780423C 90 40 100 60 60 60 60 60 0 0
Prabir Kumar Biswas     778635C 113 20 153 93 127 213 187 127 120 86
Prabodh Chandra Garai   344077C 120 33 120 67 67 170 67 100 103 103
Pradip Kumar            786171C 115 15 140 90 140 140 140 100 50 40
Purushothaman           291720C 107 63 200 40 40 87 33 40 47 54
Ragavan                 470842C 100 40 90 100 130 93 93 107 30 37
Rai                     773873C 113 60 107 160 180 167 90 160 20 90
Rajalakshmi             939143B 110 50 240 60 120 220 130 100 160 120
Rama                    834511C 100 53 120 60 60 67 60 67 7 7
Ramakani Mishra         819686C 100 55 100 50 70 130 105 55 80 75
Ramanath Maity          596897C 100 60 300 40 50 130 120 50 90 80
Ramasurey Prasad        793747C 113 40 173 50 50 130 60 50 80 80
Ramchandra Phasai       794249C 120 70 100 100 180 200 60 200 100 140
Ranu Mitra              830777C 100 20 120 55 55 160 125 55 80 75
Ratan Ghosh             737499C 110 50 60 50 50 70 100 70 50 50
Ruckmani                016357C 93 40 113 40 50 65 70 50 30 20
Sabanti Saha            083349C 120 150 150 60 120 150 170 150 110 50
Sankarlal Dey           797360C 120 30 100 60 60 130 130 65 70 70
Saroja                  815512C 107 46 120 40 40 60 60 40 20 20
Selvaraj                837975C 80 13 60 53 67 113 80 53 60 60
Shika Rani Chaki        313338B 97 50 133 40 50 150 80 147 110 100
Sisir Kumar Chakraborth 784071C 90 30 70 35 130 130 130 60 95 70
Sita Pyakurec           796030C 150 50 200 67 120 200 180 113 133 87
Subramani               824506C 20 30 100 0 10 50 30 0 50 50
Suchitra                394231C 100 60 200 50 50 80 70 60 30 30
Sulaja 829445C 80 27 60 60 73 87 90 60 30 30
Susama                  740380C 100 53 200 60 60 88 90 70 30 30
Swapan Kumar            807934C 110 80 180 80 80 210 100 190 130 130
Tek Bahaduk Singh       731552C 100 70 90 30 50 180 140 50 150 130
Thajunnisa              866887B 153 54 200 67 60 213 93 133 146 153
Thomas                  636360C 87 66 80 70 130 160 140 90 90 70
Vanitha                 828803C 120 47 90 67 60 80 80 60 13 20
Vasantha                180463B 93 87 100 50 73 120 73 127 70 54
Veddaponnammal          749961A 130 30 93 50 60 160 40 60 110 100
ABBREVIATIONS FOR THE MASTER SHEET WITH CODING
SNO                  : Serial number
Hno                   : Hospital number
Sex                    : male = 1, female =2
NYHA              : New York Heart Association Class from 1 to 4
D                       : NYHA class for dyspnoea from 1 to 4
CP                     : NYHA class for chest pain from 1 to 4
P                        : NYHA class for palpitations from 1 to 4
Fatigue              : NYHA class for fatigue from 1 to 4
Abd_dis            : Abdominal distension [Present +1, Absent = 0]
Thy_dys           : Thyroid dysfunction [euthyroid==0,hypothyroid=1,hyperthyroid=2]
HT                    : Hypertension [Present +1, Absent = 0]
DM                   : Diabetes Mellitus [Present +1, Absent = 0]
DL                    : Dyslipidemia [Present +1, Absent = 0]
IHD                  : Ischemic heart disease [Present +1, Absent = 0]
Sm                    : Smoking [Present +1, Absent = 0]
Al                     : Alcohol consumption [Present +1, Absent = 0]
BP                    : Blood pressure [Present +1, Absent = 0]
JVP                  : Jugular venous pressure [ Elevated = 1, normal = 0]
S3                    : Presence of third heart sound [Present +1, Absent = 0]
S4                    : Presence of fourth heart sound [Present +1, Absent = 0]
QRS                : Duration of qrs in msec
LVIDD           : Left ventricular internal diameter in diastole
LVIDS        : Left ventricular internal diameter in systole
EDV             : End diastolic volume
ESV             : End systolic volume
EF                 : Ejection fraction
MR               : Grade of MR [0=absent,1=mild,2=moderate,3=severe]
TR                : Grade of TR [0=absent,1=mild,2=moderate,3=severe]
AR                : Grade of AR [0=absent,1=mild,2=moderate,3=severe]
APED           : Aortic preejection delay in msec
PPED           :  Pulmonary preejection delay in msec
IVMD          : Intraventricular delay in msec
SPMD          : Septum to posterior wall motion delay in msec
Qrl              :  Isovolumic contraction time from Q to RV basal lateral wall in msec
Qbs             :  Isovolumic contraction time from Q to basal septum in msec
Qbl             :  Isovolumic contraction time from Q to basal lateral wall in msec
Qba            :  Isovolumic contraction time from Q to basal anterior wall in msec
Qbi            :  Isovolumic contraction time  from Q to basal inferior wall in msec
RVLV      :  Interventricular dyssynchrony in msec
LVDYS   :  Intraventricular dyssynchrony in msec
    
